POSITIVEID (PSID) 10-Q15 May 152015 Q1 Quarterly reportFinancial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
Document And Entity Information	Mar. 31, 2015	11-May-15
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Entity Registrant Name	POSITIVEID Corp
Entity Central Index Key	1347022
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Trading Symbol	PSID
Entity Common Stock, Shares Outstanding		262,145,065

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Current Assets:
Cash and cash equivalents	$598	$145
Prepaid expenses and other current assets	10	5
Total Current Assets	608	150
Property and Equipment, net	1	3
Goodwill	510	510
Intangibles, net	285	347
Other assets	11	11
Total Assets	1,415	1,021
Current Liabilities:
Accounts payable	116	127
Accrued expenses and other current liabilities	650	693
Deferred revenue	2,505	2,571
Tax contingency	395	480
Notes payable	601	676
Short-term convertible debt, net of discounts and premiums	1,409	1,527
Embedded conversion option liability	4,034	2,152
Total Current Liabilities	9,710	8,226
Long Term liabilities:
Mandatorily redeemable Series I preferred stock, 2,500 shares authorized; $0.001 par value; 1,625 and 1,000 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively; liquidation preference and redemption value of $1,713 and $1,065 at March 31, 2015 and December 31, 2014, respectively	2,077	1,241
Total Liabilities	11,787	9,467
Commitments and contingencies (Note 7)
Stockholdersâ€™ Deficit:
Convertible preferred stock, 5,000,000 shares authorized, $.001 par value; Series F Preferred - nil shares issued and outstanding at December 31, 2014 and March 31, 2015	0	0
Common stock, 1,970,000,000 shares authorized, $.01 par value; 236,550,328 and 169,531,322 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively	2,365	1,695
Additional paid-in capital	123,881	122,616
Accumulated deficit	-136,618	-132,757
Total Stockholdersâ€™ Deficit	-10,372	-8,446
Total Liabilities and Stockholdersâ€™ Deficit	$1,415	$1,021

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets [Parenthetical] (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Common Stock, Shares Authorized	1,970,000,000	1,970,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)	$0.01	$0.01
Common Stock, Shares, Issued	236,550,328	169,531,322
Common Stock, Shares, Outstanding	236,550,328	169,531,322
Series I Preferred Stock [Member]
Mandatorily Redeemable Preferred Stock Par Or Stated Value Per Share (in dollars per share)	$0.00	$0.00
Mandatorily Redeemable Preferred Stock Shares Authorized	2,500	2,500
Mandatorily Redeemable Preferred Stock, Shares Issued	1,625	1,000
Mandatorily Redeemable Preferred Stock, Shares Outstanding	1,625	1,000
Mandatorily Redeemable Preferred Stock, Liquidation Preference Value	$1,713	$1,065
Series F Preferred Stock [Member]
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$0.00	$0.00
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Revenue	$131	$0
Operating expenses:
Direct Labor	103	0
Selling, general and administrative	1,788	1,831
Research and development	296	147
Total operating expenses	2,187	1,978
Operating loss	-2,056	-1,978
Other income (expense):
Interest expense	-1,125	-332
Change in fair value of embedded conversion option liability	-696	0
Loss on extinguishment of debt	-104	0
Other income (expense)	120	0
Interest and other expense, net	-1,805	-332
Net loss	-3,861	-2,310
Preferred stock dividends	-23	-26
Beneficial conversion dividend on preferred stock	0	-396
Net loss attributable to common stockholders	($3,884)	($2,732)
Net loss per common share attributable to common stockholders - basic and diluted (in dollars per share)	($0.02)	($0.05)
Weighted average shares outstanding - basic and diluted (in shares)	199,287	59,058

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement of Changes in Stockholders' Deficit (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
In Thousands, except Share data	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2014	($8,446)	$1,695	$122,616	($132,757)
Balance (in Shares) at Dec. 31, 2014		169,532,000
Net loss	-3,861	0	0	-3,861
Stock based compensation	172	46	126	0
Stock based compensation (in shares)		4,600,000
Preferred stock dividends	-23	0	-23	0
Common Stock issued pursuant to convertible note conversions	907	624	283	0
Common Stock issued pursuant to convertible note conversions (in shares)		62,418,000
Reclassification of premium upon debt conversion and redemption	126	0	126	0
Reclassification of derivative liability upon debt conversion	753	0	753	0
Balance at Mar. 31, 2015	($10,372)	$2,365	$123,881	($136,618)
Balance (in shares) at Mar. 31, 2015		236,550,000

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net loss	($3,861)	($2,310)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	63	83
Stock-based compensation	985	1,158
Convertible debt discounts and premium amortization	1,008	60
Loss on extinguishment of debt	24	0
Change in fair value of embedded conversion option liability	696	0
Non-cash interest expense	116	261
Decrease in tax contingency	-85	0
Increase in fair value of contingent earn-out liability	0	100
Gain on sale of stock from investment shares	-95	0
Note issued as consideration for services	25	0
Changes in operating assets and liabilities:
Decrease (increase) in prepaid expenses and other current assets	-5	1
(Decrease) increase in accounts payable and accrued expenses	-54	22
Decrease in deferred revenue	-65	0
Net cash used in operating activities	-1,248	-625
Cash flows from investing activities:
Proceeds from sale of stock from investment shares	95	0
Net cash provided by investing activities	95	0
Cash flows from financing activities:
Proceeds from issuances of Series F Preferred Stock, net of fees	0	100
Proceeds from debt financing, net of fees	1,858	456
Payments on short-term debt	-252	0
Net cash provided by financing activities	1,606	556
Net (decrease) increase in cash and cash equivalents	453	-69
Cash and cash equivalents, beginning of period	145	165
Cash and cash equivalents, end of period	598	96
Supplementary Cash Flow Information:
Cash paid for interest	20	0
Cash paid for income tax	0	0
Non-cash financing and investing activities:
Preferred dividends converted into common stock	0	14
Conversion of promissory notes into common stock	907	95
Beneficial conversion value recognized as dividend in Series F preferred stock conversions	0	396
Reclassification of embedded conversion option liability upon conversion of debt	753	0
Reclassification of stock settle debt premium to equity upon conversion of debt	126	0
Issuance of shares for services	0	273
Discounts recorded for loan fees and OID	292	0
Embedded conversion option liability recorded as debt discount	$1,939	$0

Organization_and_Basis_of_Pres

Organization and Basis of Presentation	3 Months Ended
Organization and Basis of Presentation	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Description and Basis of Presentation [Text Block]	1. Organization and Basis of Presentation

	PositiveID Corporation, including its wholly owned subsidiary MicroFluidic Systems (“MFS”) (collectively, the “Company” or “PositiveID”), develops molecular diagnostic systems for bio-threat detection, for rapid diagnostic testing, and also develops assays to detect a range of biological threats. The Company’s M-BAND (Microfluidic Bio-agent Autonomous Networked Detector) system is an airborne bio-threat detection system developed for the homeland defense industry, to detect biological weapons of mass destruction. The Company is also developing the handheld automated pathogen detection system Firefly Dx for rapid diagnostics, both for point of need and clinical applications.

	PositiveID is a Delaware corporation formed in 2001. The Company commenced operations in 2002 as VeriChip Corporation. In 2007, the Company completed an initial public offering of its common stock.

	Authorized Common Stock

	As of March 31, 2015, the Company was authorized to issue 970 million shares of common stock. On April 30, 2015, the Company filed the Sixth Amendment to the Second Amendment and Restated Certificate of Incorporation, as amended, with the State of Delaware to increase the number of authorized common shares to 1.97 billion shares.

	Going Concern

	The Company’s unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. As of March 31, 2015, we had a working capital deficiency of approximately $9.1 million and an accumulated deficit of approximately $136.6 million, compared to a working capital deficit of approximately $8.1 million and an accumulated deficit of approximately $132.8 million as of December 31, 2014. The decrease in working capital was primarily due to historical operating losses and a net loss of $3.9 million during the three months ended March 31, 2015, offset by cash received from capital raised through convertible debt financings. In addition, the Company used cash in operations of $1.2 million during the three months ended March 31, 2015.

	We have incurred operating losses prior to and since the merger that created PositiveID. The current 2015 operating losses are the result of research and development expenditures and selling, general and administrative expenses related to our molecular diagnostics and detection products. We expect our operating losses to continue through 2015. These conditions raise substantial doubt about our ability to continue as a going concern.

	Our ability to continue as a going concern is dependent upon our ability to obtain financing to fund the continued development of our products and to support working capital requirements. Until we are able to achieve operating profits, we will continue to seek to access the capital markets. During the three months ended March 31, 2015, we raised approximately $1.6 million from the issuance of convertible debt, net of payments.

	The Company intends to continue to access capital to provide funds to meet its working capital requirements for the near-term future. In addition and if necessary, the Company could reduce and/or delay certain discretionary research, development and related activities and costs. However, there can be no assurances that the Company will be able to negotiate additional sources of equity or credit for its long term capital needs. The Company’s inability to have continuous access to such financing at reasonable costs could materially and adversely impact its financial condition, results of operations and cash flows, and result in significant dilution to the Company’s existing stockholders. The Company’s consolidated financial statements do not include any adjustments relating to recoverability of assets and classifications of assets and liabilities that might be necessary should the Company be unable to continue as a going concern.

	Basis of Presentation

	The accompanying consolidated balance sheet as of December 31, 2014 has been derived from the Company’s audited financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2014. The accompanying unaudited condensed consolidated financial statements for the three months ended March 31, 2015 and three months ended March 31,2014 have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities Exchange Commission (“SEC”). Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. In the opinion of the Company’s management, all adjustments (including normal recurring adjustments) necessary for a fair presentation for the periods presented have been reflected as required by Regulation S-X, Rule 10-01.

	The unaudited condensed consolidated statements of operations for the three months ended March 31, 2015 are not necessarily indicative of the results that may be expected for the entire year. These statements should be read in conjunction with the consolidated financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.

	New Accounting Pronouncements

	There are no new accounting pronouncements during the three months ended March 31, 2015 that affect the consolidated financial position of the Company or the results of its’ operations. Accounting Standard Updates which are not effective until after March 31, 2015, including the pronouncements discussed below, are not expected to have a significant effect on the Company’s consolidated financial position or results of its’ operations.

	ASU 2014 – 09:

	In June 2014, FASB issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers”. The update gives entities a single comprehensive model to use in reporting information about the amount and timing of revenue resulting from contracts to provide goods or services to customers. The proposed ASU, which would apply to any entity that enters into contracts to provide goods or services, would supersede the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification. Additionally, the update would supersede some cost guidance included in Subtopic 605-35, Revenue Recognition – Construction-Type and Production-Type Contracts. The update removes inconsistencies and weaknesses in revenue requirements and provides a more robust framework for addressing revenue issues and more useful information to users of financial statements through improved disclosure requirements. In addition, the update improves comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. The update is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. This updated guidance is not expected to have a material impact on our results of operations, cash flows or financial condition.

	ASU 2014-12:

	In June 2014, FASB issued Accounting Standards Update (“ASU”) No. 2014-12, “Compensation – Stock Compensation (Topic 718); Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period”. The amendments in this ASU apply to all reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. The amendments require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Topic 718 as it relates to awards with performance conditions that affect vesting to account for such awards. For all entities, the amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. The effective date is the same for both public business entities and all other entities.

	Entities may apply the amendments in this ASU either (a) prospectively to all awards granted or modified after the effective date or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. If retrospective transition is adopted, the cumulative effect of applying this Update as of the beginning of the earliest annual period presented in the financial statements should be recognized as an adjustment to the opening retained earnings balance at that date. Additionally, if retrospective transition is adopted, an entity may use hindsight in measuring and recognizing the compensation cost. This updated guidance is not expected to have a material impact on our results of operations, cash flows or financial condition.

	ASU 2014-15:

	In August 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40); Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. This update requires management of the Company to evaluate whether there is substantial doubt about the Company’s ability to continue as a going concern. This update is effective for the annual period ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. The Company does not expect this standard to have an impact on the Company’s consolidated financial statements upon adoption.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies

	Principles of Consolidation

	The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries of which all are inactive except for MFS. All significant intercompany transactions have been eliminated in the consolidation.

	Use of Estimates

	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates during the reported periods include allowance for doubtful accounts receivable, valuation of goodwill and intangible assets, valuation of derivatives, valuation of beneficial conversion features, estimate of the contingent earn-out liability, valuation of stock-based compensation and an estimate of the deferred tax asset valuation allowance.

	Intangible Assets and Goodwill

	Intangible assets are carried at cost less accumulated amortization, computed using the straight-line method over the estimated useful lives. Customer contracts and relationships were previously being amortized over 3 years, patents are being amortized over 5 years, and non-compete agreements were previously being amortized over 2 years.

	The Company continually evaluates whether events or circumstances have occurred that indicate the remaining estimated useful lives of its definite-lived intangible assets may warrant revision or that the remaining balance of such assets may not be recoverable. The Company uses an estimate of the related undiscounted cash flows attributable to such asset over the remaining life of the asset in measuring whether the asset is recoverable.

	The Company records goodwill as the excess of the purchase price over the fair values assigned to the net assets acquired in business combinations. Goodwill is allocated to reporting units as of the acquisition date for the purpose of goodwill impairment testing. The Company’s reporting units are those businesses for which discrete financial information is available and upon which segment management makes operating decisions. Goodwill of a reporting unit is tested for impairment at year-end, or between testing dates if an impairment condition or event is determined to have occurred.

	In assessing potential impairment of the intangible assets recorded in connection with the MFS acquisition as of March 31, 2015, we considered the likelihood of future cash flows attributable to such assets, including but not limited to cash received from Boeing and the probability and extent of our participation in the DHS’s next generation BioWatch program and the what we believe to be a large market opportunity for our Firefly Dx product, once development is complete. Based on our analysis, we have concluded based on information currently available, that no impairment of the intangible assets exists as of March 31, 2015.

	The Company performed an impairment test of goodwill as indicators were present as of March 31, 2015. As a result of this test, using the market capitalization method of valuation, it was determined that the goodwill balance of $510,000 as of March 31, 2015, was not impaired.

	Convertible Notes With Variable Conversion Options

	The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into common shares at a fixed discount to the price of the common stock at the time of conversion. The Company measures the fair value of the notes at the time of issuance, which is the result of the share price discount at the time of conversion, and records the premium as accretion to interest expense to the date of first conversion.

	The Company accounts for debt issuance cost paid to lenders, or on behalf of lenders, in accordance with ASC 470, Debt. The costs associated with the issuance of debt are recorded as debt discount and amortized over the life of the underlying debt instrument.

	Accounting for Derivatives

	The Company evaluates its convertible debt, options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for. The result of this accounting treatment is that under certain circumstances the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Equity instruments that are initially classified as equity that become subject to reclassification under this accounting standard are reclassified to liability at the fair value of the instrument on the reclassification date.

	Revenue Recognition

	Revenue is recognized when persuasive evidence of an arrangement exists, collectability of arrangement consideration is reasonably assured, the arrangement fees are fixed or determinable and delivery of the product or service has been completed.

	If at the outset of an arrangement, the Company determines that collectability is not reasonably assured, revenue is deferred until the earlier of when collectability becomes probable or the receipt of payment. If there is uncertainty as to the customer’s acceptance of the Company’s deliverables, revenue is not recognized until the earlier of receipt of customer acceptance or expiration of the acceptance period. If at the outset of an arrangement, the Company determines that the arrangement fee is not fixed or determinable, revenue is deferred until the arrangement fee becomes estimable, assuming all other revenue recognition criteria have been met.

	To date, the Company has generated revenue from two sources: (1) professional services (consulting & advisory), and (2) technology licensing.

	Specific revenue recognition criteria for each source of revenue is as follows:

		-1	Revenues for professional services, which are of short term duration, are recognized when services are provided,

		-2	Technology license revenue is recognized upon the completion of all terms of that license. Payments received in advance of completion of the license terms are recorded as deferred revenue.

	Fair Value of Financial Instruments and Fair Value Measurements

	The Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with ASC Topic 820, Fair Value Measurements and Disclosures (“ASC Topic 820”). For certain of our financial instruments, including cash, accounts receivable, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, also approximate fair value because current interest rates available to the Company for debt with similar terms and maturities are substantially the same.

	ASC Topic 820 provides guidance with respect to valuation techniques to be utilized in the determination of fair value of assets and liabilities. Approaches include, (i) the market approach (comparable market prices), (ii) the income approach (present value of future income or cash flow), and (iii) the cost approach (cost to replace the service capacity of an asset or replacement cost). ASC Topic 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

		Level 1:	Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

		Level 2:	Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

		Level 3:	Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

	Loss per Common Share

	The Company presents basic income (loss) per common share and, if applicable, diluted income (loss) per share. Basic income (loss) per common share is based on the weighted average number of common shares outstanding during the year and after preferred stock dividend requirements. The calculation of diluted income (loss) per common share assumes that any dilutive convertible preferred shares outstanding at the beginning of each year or the date issued were convertible at those dates, with preferred stock dividend requirements and outstanding common shares adjusted accordingly. It also assumes that outstanding common shares were increased by shares issuable upon exercise of those stock options and warrants for which the average period market price exceeds the exercise price, less shares that could have been purchased by the Company with related proceeds. Additionally, shares issued upon conversion of convertible debt are included.

	The following potentially dilutive equity securities outstanding as of March 31, 2015 and 2014 were not included in the computation of dilutive loss per common share because the effect would have been anti-dilutive (in thousands):

		March 31,
		2015		2014
Common shares issuable under:
Convertible notes			245,375		12,254
Series I Convertible preferred stock			62,064		36,460
Series F Convertible preferred stock			—		35,887
Stock options			4,696		2,607
Warrants			4,490		2,629
Unvested and restricted shares common stock			3,432		2,432
			320,057		92,269

Segment Information

The Company operates in a single market segment.

AcquisitionsDispositions

Acquisitions/Dispositions	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block Supplement [Abstract]
Mergers, Acquisitions and Dispositions Disclosures [Text Block]	3. Acquisitions/Dispositions

	Sale of VeriChip Business to Former Related Party

	In a series of transactions between 2012 and 2014 PositiveID first licensed and subsequently sold all of the intellectual property related to its VeriChip implantable microchip business to VeriTeQ Corporation, a business run by a former related party (CEO of the Company through 2011). The final agreement in the series was the GlucoChip Agreement, dated October 20, 2014.

	Pursuant to the VeriTeQ agreements, the Company holds a Note that was received as payment for shared services payments that the Company made on behalf of VeriTeQ during 2011 and 2012 which Note had an original value of $222,115. The note has been fully reserved in all periods presented. The Company also holds a five year warrant dated November 13, 2013, with original terms entitling the Company to purchase 300,000 shares of VeriTeQ common stock at a price of $2.84. Pursuant to the terms of the warrant, in particular the full quantity and pricing reset provisions, the warrant had an original dollar value of $852,000 and can be exercised using a cashless exercise feature.

	Pursuant to the GlucoChip Agreement, the Company transferred the intellectual property related to its GlucoChip development and agreed to provide financial support to VeriTeQ, for a period of up to two years, in the form of convertible promissory notes. On October 20, 2014, and January 29, 2015, the Company funded VeriTeQ $60,000 and $40,000, respectively and VeriTeQ issued the Company Convertible Promissory Notes in the principal amount of $60,000 and $40,000, respectively. These notes have been fully reserved in all periods presented. The notes bear interest at the rate of 10% per annum; are due and payable on October 20, 2015 and January 29, 2016; and may be converted by the Company at any time after 190 days of the date of closing into shares of VeriTeQ common stock at a conversion price equal to a 40% discount of the average of the three lowest daily trading prices (as set forth in the notes) calculated at the time of conversion. The notes also contains certain representations, warranties, covenants and events of default, and increases in the amount of the principal and interest rates in the event of such defaults. Pursuant to the GlucoChip Agreement, the Company agreed to provide VeriTeQ with continuing financial support through issuance of additional convertible promissory notes with similar terms and conditions as the original note up to an additional amount of $300,000 (see Note 7). The continuing financial support is not required to be more frequent than every 100 days and may not be in excess of $50,000 in any individual note.

	As of December 31, 2014 and March 31, 2015 the Company had convertible notes receivable from VeriTeQ of $282,115 and $322,115, respectively. As of December 31, 2014 and March 31, 2015 the Company had a dollar value balance remaining on it cashless exercise warrant from VeriTeQ of $820,010 and $781,376, respectively.

	Pursuant to the cashless exercise feature fo the VeriTeQ warrant, the Company realized $95,000 of income during the three months ended March 31, 2015. As VeriTeQ is an early stage company, not yet fully capitalized, the Company plans to continue to fully reserve all note receivable and warrant balances. If and when proceeds are realized in the future, gains all be recognized.

	License of iglucose

	On February 15, 2013, the Company entered into an agreement the (“SGMC Agreement”) with SGMC, Easy Check, Easy-Check Medical Diagnostic Technologies Ltd., an Israeli company, and Benjamin Atkin, an individual (“Atkin”), pursuant to which the Company entered into a perpetual license to its iglucose ™ technology to SGMC for up to $2 million based on potential future revenues of glucose test strips sold by SGMC. These revenues will range between $0.0025 and $0.005 per strip. A person with diabetes who tests three times per day will use over 1,000 strips per year.

	Pursuant to the SGMC Agreement, the Company granted SGMC an exclusive right and license to the intellectual property rights in the iglucose patent applications; a non-exclusive right and license to use and make a “white label” version of the iglucose websites; a non-exclusive right and license to use all documents relating to the iglucose 510(k) application to the Food and Drug Administration of the United States Government; and an exclusive right and license to the iglucose trademark. The Company has also agreed to transfer to SGMC all right, title, and interest in the www.iglucose.com and www.iglucose.net domain names.

	In consideration for the rights and licenses discussed above, and the transfer of the domain names, SGMC shall pay to the Company the amount set forth below for each glucose test strip sold by SGMC and any sublicenses of SGMC for which results are posted by SGMC via its communications servers (the “Consideration”):

		(i)	$0.0025 per strip sold until SGMC has paid aggregate Consideration of $1,000,000; and
		(ii)	$0.005 per strip sold thereafter until SGMC has paid aggregate Consideration of $2,000,000; provided, however, that the aggregate Consideration payable by SGMC pursuant to the SGMC Agreement shall in no event exceed $2,000,000.

	To date, no royalties have been realized from this agreement.

Equity_and_Debt_Financing_Agre

Equity and Debt Financing Agreements

3 Months Ended

Mar. 31, 2015

Equity And Debt Financing Agreements Disclosure [Abstract]

Equity And Debt Financing Agreements Disclosure [Text Block]

4. Equity and Debt Financing Agreements

Convertible Note Financings

Short-term convertible debt for the quarter ended March 31, 2015 as follows (In thousands):

Notes

Accrued

Total

Interest

Convertible notes with accrued interest accounted for as stock settled debt

379

413

Conversion premiums

261

—

261

640

674

Convertible notes with embedded derivatives

3,229

137

3,366

Derivative discounts

-2,259

—

-2,259

970

137

1,107

Original issue discounts and loan fee discounts

-372

—

-372

1,238

171

1,409

$4 Million Convertible Debt Financing

On November 25, 2014 the Company closed a financing transaction by entering into a Securities Purchase Agreement dated November 25, 2014 (the “SPA”) with Dominion Capital LLC (the “Purchaser”) for an aggregate subscription amount of $4,000,000 (the “Purchase Price”). Pursuant to the Securities Purchase Agreement, the Company shall issue a series of 4% Original Issue Discount Senior Secured Convertible Promissory Notes (collectively, the “Notes”) to the Purchaser. The Purchase Price will be paid in eight equal monthly payments of $500,000. Each individual Note will be issued upon payment and will be amortized beginning six months after issuance, with amortization payments being 1/24^th of the principal and accrued interest, made in cash or common stock at the option of the Company, subject to certain conditions contained in the Securities Purchase Agreement. The Company also reimbursed the Purchaser $25,000 for expenses from the proceeds of the first tranche and the Purchaser’s counsel $25,000 from the first tranche. The use of proceeds from this financing are intended for the completion of the breadboard prototype of the Company’s Firefly Dx cartridge, restructuring of the Company’s existing convertible debt, and general working capital.

The total principal amount of the Notes are issued with a 4% original issue discount whereby the principal amount of the Note is $4,000,000 but the actual purchase price of the note is $3,840,000. Each Note accrues interest at a rate equal to 12% per annum and has a maturity date of May 25, 2016. The Notes are convertible any time after the issuance date of the Notes. The Purchasers has the right to convert the Notes into shares of the Company’s common stock at a conversion price equal to 95% of the daily VWAP on the trading day immediately prior to the closing of each tranche. Additionally, under certain conditions defined in the Note, the Note would be convertible into common stock at a price equal to 62.5% of the lowest VWAP during the 15 Trading Days immediately prior to the applicable amortization date. In the event that there is an Event of Default or certain conditions are not met, the conversion price will be adjusted to equal to 55% of the lowest VWAP during the thirty (30) Trading Days immediately prior to the applicable Conversion Date. The Note can be prepaid at any time upon five days’ notice to the Holder by paying an amount in cash equal to the outstanding principal and interest and a 120% premium.

In connection with the Company’s obligations under the Note, the Company entered into a Security Agreement with the Purchaser, pursuant to which the Company granted a lien on all assets of the Company, subject to existing security interests, (the “Collateral”) for the benefit of the Purchaser, to secure the Company’s obligations under the Note. In the event of a default as defined in the Note, the Purchaser may, among other things, collect or take possession of the Collateral, proceed with the foreclosure of the security interest in the Collateral or sell, lease or dispose of the Collateral.

Through March 31, 2015, the Company has received the first five of the eight tranches under the SPA of the Note ($500,000 in 2014 and $2,150,000 in 2015 which includes an additional $150,000 added to one of the agreed $500,000 monthly fundings as requested by the Company), with maturity dates, depending on the date funded, between June 26, 2016 and September 26, 2016, pursuant to a convertible note. Under the agreement the Company received $2,244,600, which was net of the $299,400 Purchaser’s expenses and legal fees and $106,000 which represents the 4% original issue discount. The note might be accelerated if an event of default occurs under the terms of the note, including the Company’s failure to pay principal and interest when due, certain bankruptcy events or if the Company is delinquent in its SEC filings. In connection with the issuance of the note, the Company recorded a debt discount of $387,000 in 2014 and $1,857,600 for the quarter ended March 31, 2015, related to the embedded conversion option derivative liability. The amortization expense related to that discount recorded was $27,000 in 2014 and $276,357 during the quarter ended March 31, 2015. As of March 31, 2015, the outstanding principal and interest on the notes was $2,716,460. As the note conversion includes a “lesser of” pricing provision, a derivative liability of $3,610,885 was recorded when the note was entered into. The derivative liability is remeasured at each balance sheet date and was $3,474,979 at March 31, 2015.

Other Convertible Debt Financing

On March 13, 2014, the Company borrowed two notes of $75,000, each from a separate lender with maturity dates of March 4, 2015. Under each agreement the Company received $65,750, which was net of legal and due diligence fees. The notes bear interest at 8% per annum and are convertible at the option of the lender into shares of the Company’s common stock at a 40% discount to the lowest closing bid price in the 20 trading days prior to conversion. The notes might be accelerated if an event of default occurs under the terms of the note, including the Company’s failure to pay principal and interest when due, certain bankruptcy events or if the Company is delinquent in its SEC filings. In conjunction with each note the Company also issued an additional note, of identical terms, each for $75,000. The additional note was paid for by the issuance of a note payable from the lenders to the Company. In the event that the original note is not repaid prior to six months from its issuance, the lender has the option of converting the additional note into shares of the Company’s common stock at a 40% discount to lowest closing bid price in the 20 trading days prior to conversion, subject to the notes payable to the Company having been paid in full. The additional note payable has been netted with the related note receivable. In connection with the issuance of the notes, the Company computed a premium of $100,000 as the debt is considered a stock settled debt under ASC 480, all of which was amortized during the year ended December 31, 2014. As of March 31, 2015, the outstanding principal and interest was converted, into 16,386,485 shares of common stock. On May 5, 2014 one of the $75,000 notes receivable due to the company was paid, for which the Company received $65,750, net of fees. The Company computed a premium of $50,000 as the debt is considered a stock settled debt under ASC 480, all of which was amortized during the year ended December 31, 2014. As of March 31, 2015, the outstanding principal and interest was converted, into 4,117,795 shares of common stock. Concurrent with the repayment the Company and the lender entered into two new convertible notes, for $75,000 each, on identical terms to the March 4, 2014 convertible notes. Each of these two notes was paid for by the issuance of notes payable from the lenders to the Company, each for $75,000, on identical terms to the March 4, 2014 notes. These two new notes have been netted for presentation purposes. In connection with the payment of the note receivable to the Company, the Company recorded a premium of $50,000 for each of the additional notes that had been entered into on March 4, 2014, all of which was amortized during the year ended December 31, 2014. During the three months ended March 31, 2015, the outstanding principal and interest for both notes was converted, into 9,482,870 shares of common stock.

On June 18, 2014, the Company closed a financing agreement whereby the Company borrowed an aggregate principal amount of $165,000 with a 10% original note discount. The note has an interest rate of 10%, and is convertible at the option of the lender into shares of the Company’s common stock at the lesser of (i) a 40% discount to the lowest closing bid price in the 20 trading days prior to conversion or (ii) $0.075. The note might be accelerated if an event of default occurs under the terms of the note, including the Company’s failure to pay principal and interest when due, certain bankruptcy events or if the Company is delinquent in its SEC filings. The first tranche was funded on June 18, 2014 with a principal amount of $55,000 and net proceeds of $50,000, with a maturity date of June 17, 2016, pursuant to the convertible note. In connection with the issuance of the note, the Company recorded a debt discount of $50,000 related to the derivative liability. The amortization expense related to that debt discount recorded as of March 31, 2015 was $56,394. During the quarter ended March 31, 2015, $51,051 of the outstanding principal and interest on the note was converted into 3,750,000 shares of common stock and the remaining balance of the note as of March 31, 2015 was $8,545. As the note conversion includes a “lesser of” pricing provision, a derivative liability of $59,623 was recorded when the note was entered into. The derivative liability is re-measured at each balance sheet date and was $5,712 at March 31, 2015. The second tranche was funded on September 19, 2014, with a principal amount of $55,000 and net proceeds of $50,000, with a maturity date of September 19, 2015, pursuant to a convertible note. In connection with the issuance of the notes, the Company recorded a debt discount of $50,000 related to the derivative liability. The amortization expense related to that discount recorded as of quarter ended March 31, 2015 was $25,048. As of March 31, 2015, the outstanding principal and interest on the notes was $58,195. As the note conversion includes a “lesser of” pricing provision, a derivative liability of $59,623 was recorded when the note was entered into. The derivative liability is re-measured at each balance sheet date and was $42,026 at March 31, 2015. The third tranche was funded on December 22, 2014, with a principal amount of $55,000 and net proceeds of $50,000, with a maturity date of December 22, 2015, pursuant to a convertible note. In connection with the issuance of the note, the Company recorded a debt discount of $50,000 related to the derivative liability. The amortization expense related to that discount recorded as of quarter ended March 31, 2015 was $28,193. As of March 31, 2015, the outstanding principal and interest on the notes was $56,492. As the note conversion includes a “lesser of” pricing provision, a derivative liability of $62,858 was recorded when the note was entered into. The derivative liability is re-measured at each balance sheet date and was $48,978 at March 31, 2015.

On July 3, 2014, the Company borrowed $115,000 with a maturity date of July 3, 2015, pursuant to a convertible note. Under the agreement the Company received $100,000, which was net of legal and due diligence fees. The Note has an interest rate of 8%, and is convertible at the option of the lender into shares of the Company’s common stock at the lesser of $0.06 per share or a 40% discount of the lowest closing bid prices in the 15 trading days prior to conversion. The note might be accelerated if an event of default occurs under the terms of the note, including the Company’s failure to pay principal and interest when due, certain bankruptcy events or if the Company is delinquent in its SEC filings. In connection with the issuance of the notes, the Company recorded a debt discount of $58,571 relating to derivative liability which was fully amortized as of quarter ended March 31, 2015. During quarter ended March 31, 2015, the outstanding principal and interest on the note was fully converted into 8,248,677 shares of common stocks. In conjunction with the Note, the Company granted the lender a warrant for 1,000,000 common shares at a strike price of $0.08. The warrant has a life of three years and its relative fair value of $41,429 has been recorded as a debt discount and additional paid in capital as of March 31, 2015. As the note conversion includes a “lesser of” pricing provision, a derivative liability of $59,623 was recorded when the note was entered into. The derivative liability was re-measured at each balance sheet date and was reclassified to equity on a pro-rata basis upon conversion of the note.

On July 7, 2014, the Company borrowed $53,000 with a maturity date of March 25, 2015, pursuant to a financing agreement. Under the agreement the Company received $50,000, which was net of legal fees. The note bears interest at 8% per annum and is convertible at the option of the lender into shares of the Company’s common stock at a 39% discount to the price of common shares in the 10 days prior to conversion. The note might be accelerated if an event of default occurs under the terms of the note, including the Company’s failure to pay principal and interest when due, certain bankruptcy events or if the Company is delinquent in its SEC filings. In connection with the issuance of the note, the Company computed a premium of $33,885 as the note is considered stock settled debt under ASC 480, all of which was accreted and charged to interest expense in the year ended December 31, 2014. As of quarter ended March 31, 2015, the outstanding principal and interest on the notes was $56,182.

On July 9, 2014 and August 21, 2014 the Company borrowed from a lender, notes each amounting to $110,000 which matures twelve months from the date of the respective notes, pursuant the agreement. Each debt was issued at a 10% original issue discount resulting in net total proceeds of $180,000, net of legal fees. The notes bear an interest rate of 10%, and are convertible at the option of the lender into shares of the Company’s common stock at a 40% discount to the lowest closing bid price during the 15 days prior to the election to conversion. The notes could have been accelerated if an event of default occurs under the terms of the note, including the Company’s failure to pay principal and interest when due, certain bankruptcy events or if the Company is delinquent in its SEC filings. In connection with the issuance of the note, the Company computed a total premium of $146,666 as the notes were considered stock settled debt under ASC 480. On December 30, 2014, the Lender and Dominion Capital LLC entered into a purchase and assignment of these notes. Subsequent to the purchase and assignment, the note was amended by the Company and the Purchaser, using the form of note identical to the notes used in the $4 Million Financing Agreement. The Company issued a new note for $222,222 convertible at the lesser of a 37.5% discount to the common stock price on the date of the note or a 37.5% discount to the price of our common stock price at the time of conversion. In conjunction with the purchase and assignment, the Company and Purchaser entered into a new note with a principal value of $49,444 as compensation for Purchaser’s costs related to the purchase and assignment. This $49,444 was expensed as a loss on debt extinguishment. In connection with the issuance of the notes, the Company recorded a debt discount of $271,666 related to the embedded conversion option derivative liability. The amortization expense related to that discount recorded as of quarter ended March 31, 2015 was $186,656. As of March 31, 2015, the outstanding principal and interest on the notes was $279,705. As the note conversions includes a “lesser of” pricing provision, a derivative liability of $289,701 was recorded when these notes were entered into. The derivative liability is re-measured at each balance sheet date and was $204,079 at March 31, 2015.

On July 17, 2014, the Company borrowed $115,000 with a maturity date of July 17, 2016, pursuant to a convertible note. The debt was issued at a 10% original issue discount resulting in proceeds of $100,000, has an interest rate of 10%, and is convertible at the option of the lender into shares of the Company’s common stock at the lesser of $0.06 per share or a 40% discount of the lowest closing bid prices in the 20 trading days prior to conversion. The note might be accelerated if an event of default occurs under the terms of the note, including the Company’s failure to pay principal and interest when due, certain bankruptcy events or if the Company is delinquent in its SEC filings. In connection with the issuance of the notes, the Company recorded a debt discount of $100,000 related to the derivative liability which was fully was fully amortized as of quarter ended March 31, 2015. On January 8, 2015, the Company exercised its right to prepay the outstanding principal and interest for a total redemption amount of $120,750. As the note conversion includes a “lesser of” pricing provision, a derivative liability of $124,666 was recorded when the note was entered into. The derivative liability was re-measured at each balance sheet date and was reclassified to equity on a pro-rata basis upon redemption of the note.

On August 19, 2014, the Company borrowed $66,000 with a maturity date of August 15, 2015, pursuant to a convertible note. The debt was issued at a 10% original issue discount resulting in proceeds of $54,500, net of legal fees. The Note has an interest rate of 8%, and is convertible at the option of the lender into shares of the Company’s common stock at the lesser of $0.06 per share or a 60% of the average of the three lowest closing bid prices 15 trading days prior to conversion. The note might be accelerated if an event of default occurs under the terms of the note, including the Company’s failure to pay principal and interest when due, certain bankruptcy events or if the Company is delinquent in its SEC filings. In connection with the issuance of the notes, the Company recorded a debt discount of $54,500 related to the derivative liability which was fully amortized as of the quarter ended March 31, 2015. During quarter ended March 31, 2015, the outstanding principal and interest on the note was fully converted into 5,000,000 shares of common stock. As the note conversion includes a “lesser of” pricing provision, a derivative liability of $71,548 was recorded when the note was entered into. The derivative liability was re-measured at each balance sheet date and was reclassified to equity on a pro-rata basis upon conversion of the note.

On September 4, 2014, the Company borrowed $110,000 pursuant to a convertible note with an OID of $10,000 resulting in cash received of $100,000.The debt matures twenty four months from the date funded, has a one-time 10% interest charge if not paid within 90 days, and is convertible at the option of the lender into shares of the Company’s common stock at the lesser of $0.042 per share or 60% of the average of the two lowest closing bid prices in the 25 trading days prior to conversion. The note might be accelerated if an event of default occurs under the terms of the note, including the Company’s failure to pay principal and interest when due, certain bankruptcy events or if the Company is delinquent in its SEC filings. In connection with the issuance of the notes, the Company recorded a debt discount of $100,000 which was fully amortized as of quarter ended March 31, 2015. During the quarter ended March 31, 2015, the outstanding principal and interest on the notes was fully converted into 9,195,341 shares of common stock. As the note conversion includes a “lesser of” pricing provision, a derivative liability of $119,246 was recorded when the note was entered into. The derivative liability was re-measured at each balance sheet date and was reclassified to equity on a pro-rata basis upon conversion of the note.

On September 22, 2014, Company closed a Securities Purchase Agreement providing for the purchase of two Convertible Redeemable Notes in the aggregate principal amount of $100,000, with the first note being in the amount of $50,000 and the second note being in the amount of $50,000. The first note was funded on September 22, 2014, with the Company receiving $45,000 of net proceeds, which was net of legal and due diligence fees. In connection with the issuance of the first note, the Company computed a premium of $33,333 as the note is considered stock settled debt under ASC 480 which had been fully amortized as of quarter ended March 31, 2015. During the quarter ended March 31, 2015, $5,199 of the outstanding principal and interest on the first note was converted into 361,073 shares of common stock. As of quarter ended March 31, 2015, the note had an outstanding balance of $47,124.The second note was initially paid for by the issuance of an offsetting $50,000 secured note issued by the lender to the Company. The second note was funded on April 24, 2015 (see Note 10), with the Company receiving $45,000 of net proceeds, which was net of legal and due diligence fees. In connection with the issuance of the second note, the Company computed a premium of $33,333 as the note is considered stock settled debt under ASC 480. The two notes bear interest at the rate of 8% per annum; are due and payable on September 15, 2015; and may be converted at the option of the lender into shares of Company common stock at a conversion price equal to a 40% discount of the lowest closing bid price calculated at the time of conversion. The two notes also contain certain representations, warranties, covenants and events of default, and increases in the amount of the principal and interest rates under the two Notes in the event of such defaults.

On September 22, 2014, the Company borrowed $54,750 with a maturity date of June 19, 2015, pursuant to a financing agreement. Under the agreement the Company received $50,000, which was net of legal and due diligence fees. The note bears interest at 8% per annum and is convertible at the option of the lender into shares of the Company’s common stock at a 40% discount to the price of common shares in the 10 days prior to conversion. The note might be accelerated if an event of default occurs under the terms of the note, including the Company’s failure to pay principal and interest when due, certain bankruptcy events or if the Company is delinquent in its SEC filings. In connection with the issuance of the note, the Company computed a premium of $36,500 as the note is considered stock settled debt under ASC 480. On March 10, 2015, the Lender and Dominion Capital LLC entered into a purchase and assignment of the note (see paragraph below), and the Company and Dominion amended the note, with the total amount owed as of March 10, 2015 at $56,778, with terms and conditions identical to Purchaser’s notes pursuant to the $4 Million Financing Agreement. Pursuant to the amendment the maturity date was extended to September 30, 2015. Additionally, on March 10, 2015, the Company and Purchaser entered into a $24,772 Senior Convertible, Redeemable Debenture of PositiveID Corporation, which was issued without proceeds as consideration for the Purchaser’s expenses in conjunction with the purchase and assignment with the Lender, including legal and transaction fees (see paragraph below). This amount was recorded as a loss on debt extinguishment. As of March 31, 2015, the Company no longer has any outstanding debt owed to the Lender. The total recorded premium was accreted and charged to interest expense upon the assignment of the convertible note.

On September 24, 2014, the Company borrowed $75,000 pursuant to the back-end note in conjunction with the March 13, 2014 financing agreement. The debt has an interest rate of 8% and the Company received proceeds of $67,750, net of fees, In the event that the original note is not repaid prior to six months from its issuance, the lender has the option of converting the additional note into shares of the Company’s common stock at a 40% discount to lowest closing bid price in the 20 trading days prior to conversion, subject to the notes payable to the Company having been paid in full. In connection with the issuance of the note, the Company computed a premium of $50,000 as the note is considered stock settled debt under ASC 480, all of which was accreted and charged to interest expense during the year ended December 31, 2014. As of quarter ended March 31, 2015, the outstanding principal and interest on the note had been converted fully converted into 4,955,411 shares of common stock.

On March 10, 2015, the Company issued a new note for $56,778 convertible at the lesser of a 37.5% discount to the common stock price on the date of the note (which was $0.0153125) or a 37.5% discount to the price of our common stock price at the time of conversion. In conjunction with the purchase and assignment, the Company and Purchaser entered into a new note with a principal value of $24,772 as compensation for Purchaser’s costs related to the purchase and assignment. This $24,772 was expensed as a loss on debt extinguishment. In connection with the issuance of the note, the Company recorded a debt discount of $81,500 related to the embedded conversion option derivative liability. The amortization expense related to that discount recorded as of quarter ended March 31, 2015 was $24,670. As of March 31, 2015, the outstanding principal and interest on the notes was $82,381. As the note conversions includes a “lesser of” pricing provision, a derivative liability of $96,915 was recorded when these notes were entered into. The derivative liability is re-measured at each balance sheet date and was $92,333 at March 31, 2015.

On October 6, 2014, the Company borrowed $53,000 with a maturity date of June 1, 2015, pursuant to a financing agreement. Under the agreement the Company received $50,000, which was net of legal fees. The note bears interest at 8% per annum and is convertible at the option of the lender into shares of the Company’s common stock at a 39% discount to the price of common shares in the 10 days prior to conversion. The note might be accelerated if an event of default occurs under the terms of the note, including the Company’s failure to pay principal and interest when due, certain bankruptcy events or if the Company is delinquent in its SEC filings. In connection with the issuance of the note, the Company computed a premium of $33,885 as the note is considered stock settled debt under ASC 480. During the quarter ended March 31, 2015, the Company exercised its right to prepay the outstanding principal and interest for a total redemption amount of $73,641. In addition, the remaining premium was accreted and charged to interest expense upon redemption of the convertible note.

On October 8, 2014, the Company borrowed $100,000 with a maturity date of March 30, 2015, pursuant to a financing agreement. Under the agreement the Company received $85,500, which was net of legal fees of $7,000 and original issue discount of $7,500. The note bears interest at 10% per annum and is convertible at the option of the lender into shares of the Company’s common stock at a 40% discount to the price of common shares in the 10 days prior to conversion. The note might be accelerated if an event of default occurs under the terms of the note, including the Company’s failure to pay principal and interest when due, certain bankruptcy events or if the Company is delinquent in its SEC filings. In connection with the issuance of the note, the Company computed a premium of $66,667 as the note is considered stock settled debt under ASC 480, all of which was accreted and charged to interest expense as the quarter ended March 31, 2015. As of March 31, 2015, the outstanding principal and interest on the notes was $104,986 which was fully converted into 7,590,186 shares of common stock subsequent to the quarter ended March 31, 2015.

On October 27, 2014, the Company borrowed $36,750 with a maturity date of October 21, 2015, pursuant to a financing agreement. Under the agreement the Company received $33,250, which was net of legal and due diligence fees. The note bears interest at 8% per annum and is convertible at the option of the lender into shares of the Company’s common stock at a 40% discount to the lowest closing bid price in the 20 trading days prior to conversion. The note might be accelerated if an event of default occurs under the terms of the note, including the Company’s failure to pay principal and interest when due, certain bankruptcy events or if the Company is delinquent in its SEC filings. In connection with the issuance of the notes, the Company recorded a premium of $24,500 as the note is considered stock settled debt under ASC 480, all of which was accreted and charged to interest expense as of quarter ended March 31, 2015. As of March 31, 2015, the outstanding principal and interest on the notes was $38,216. Subsequent to the quarter ended March 31, 2015, the Company exercised its right to prepay the outstanding principal and interest for a total redemption amount of $52,892.

On October 27, 2014, the Company borrowed $161,000 with a maturity date of October 27, 2015, pursuant to a financing agreement. Under the agreement the Company received $150,000, which was net of an original issue discount of $11,000. The note bears interest at 8% per annum and is convertible at the option of the lender into shares of the Company’s common stock at a 40% discount to the price of common shares in the 10 days prior to conversion. The note might be accelerated if an event of default occurs under the terms of the note, including the Company’s failure to pay principal and interest when due, certain bankruptcy events or if the Company is delinquent in its SEC filings. In conjunction with the Note, the Company granted the lender a warrant for 1,000,000 common shares at a strike price of $0.08. The warrant has a life of three years and its relative fair value of $33,404 has been recorded as a debt discount and additional paid in capital as of March 31, 2015. In connection with the issuance of the note, the Company computed a premium of $107,333 as the note is considered stock settled debt under ASC 480. The amortization expense related to that premium recorded during the three months ended March 31, 2015 was $52,215. As of March 31, 2015, the outstanding principal and interest on the notes was $167,422. On April 6, 2015, the original lender and Dominion Capital LLC (“Purchaser”) entered into a purchase and assignment of the note, and the Company and Purchaser amended the note, with the total amount of $166,681, with terms and conditions identical to Purchaser’s notes pursuant to the $4 Million Financing Agreement. Pursuant to the amendment the maturity date was extended to October 24, 2015. Additionally, on April 6, 2015 the Company and Purchaser entered into an $88,319 Senior Convertible, Redeemable Debenture of the Company, which was issued without proceeds as consideration for the Purchaser’s expenses in conjunction with the purchase and assignment with the Lender, including legal and transaction fees. This amount was recorded as a loss on debt extinguishment.

Convertible Debenture Financing

On December 24, 2014, the Ironridge and Dominion Capital LLC entered into a purchase and assignment of the debenture owned by Ironridge, and the Company and Dominion amended the Debenture, with the total amount owed as of December 24, 2014 at $434,592, making the note a demand note with terms and conditions identical to Purchaser’s notes pursuant to the $4 Million Financing Agreement. Pursuant to the amendment the maturity date was extended to May 31, 2015. Additionally, on December 24, 2014 the Company and Purchaser entered into a $158,400 Senior Convertible, Redeemable Debenture of PositiveID Corporation, which was issued without proceeds as consideration for the Purchaser’s expenses in conjunction with the purchase and assignment with Ironridge, including legal and transaction fees. This amount was recorded as a loss on debt extinguishment. As of December 31, 2014, the Company no longer had any outstanding debt owed to Ironridge.

In connection with the issuance of the Debenture and the Note, the Company recorded a debt discount of $522,061 related to the embedded conversion option derivative liability. The amortization expense related to that discount recorded in the quarter ended March 31, 2015 was $491,407. As of March 31, 2015, the outstanding principal and interest on the $434,592 Debenture was converted into 30,354,196 shares of common stock and the outstanding principal and interest on Note as of March 31, 2015 was $164,649. As the note conversion includes a “lesser of” pricing provision, a derivative liability of $571,387 was recorded when the note was entered into. The derivative liability is re-measured at each balance sheet date and was $165,622 at March 31, 2015.

Other Financings

On July 9, 2012, the Company issued a Secured Promissory Note (the “H&K Note”) in the principal amount of $849,510 to Holland & Knight LLP (“Holland & Knight”), its external legal counsel, in support of amounts due and owing to Holland & Knight as of June 30, 2012. The H&K Note is non-interest bearing, and principal on the H&K Note is due and payable as soon as practicably possible by the Company. The Company has agreed to remit payment against the H&K Note immediately upon each occurrence of any of the following events: (a) completion of an acquisition or disposition of any of the Company’s assets or stock or any of the Company’s subsidiaries’ assets or stock with gross proceeds in excess of $750,000, (b) completion of any financing with gross proceeds in excess of $1,500,000, (c) receipt of any revenue in excess of $750,000 from the licensing or development of any of the Company’s or the Company’s subsidiaries’ products, or (d) any liquidation or reorganization of the Company’s assets or liabilities. The amount of payment to be remitted by the Company shall equal one-third of the gross proceeds received by the Company upon each occurrence of any of the above events, until the principal is repaid in full. If the Company receives $3,000,000 in gross proceeds in any one financing or licensing arrangement, the entire principal balance shall be paid in full. The H&K Note was secured by substantially all of the Company’s assets pursuant to a security agreement between the Company and Holland & Knight dated July 9, 2012. In conjunction with the TCA Purchase Agreement and the Boeing License Agreement (defined below), Holland & Knight agreed to terminate its security interest. As of March 31, 2015, the Company had repaid $340,556 of the H&K Note and the outstanding balance was $508,594 which is included in notes payable on the consolidated balance sheet.

On September 7, 2012, the Company issued a Secured Promissory Note (the “Caragol Note”) in the principal amount of $200,000 to William J. Caragol (“Caragol”), the Company’s chairman and chief executive officer, in connection with a $200,000 loan to the Company by Caragol. The Caragol Note accrues interest at a rate of 5% per annum, and principal and interest on the Caragol Note are due and payable on September 6, 2013. The Company agreed to accelerate the repayment of principal and interest in the event that the Company raises at least $1,500,000 from any combination of equity sales, strategic agreements, or other loans, with no prepayment penalty for any pay-down prior to maturity. The Caragol Note was secured by a subordinated security interest in substantially all of the assets of the Company pursuant to a Security Agreement between the Company and Caragol dated September 7, 2012 (the “Caragol Security Agreement”). The Caragol Note may be accelerated if an event of default occurs under the terms of the Caragol Note or the Caragol Security Agreement, or upon the insolvency, bankruptcy, or dissolution of the Company. In December, 2012, the Company paid $100,000 of the principal amount of the Caragol Note and all accrued interest owed on the date of payment. In conjunction with the TCA Purchase Agreement and the Boeing License Agreement (defined below), Caragol agreed to terminate his security interest, effective January 16, 2013. As of March 31, 2015, the outstanding principal and interest on the Caragol Note was $91,572 which is included in notes payable on the consolidated balance sheet.

Embedded Conversion Option Derivatives

Due to the conversion terms of certain promissory notes, the embedded conversion options met the criteria to be bifurcated and presented as derivative liabilities. The Company calculated the estimated fair values of the liabilities for embedded conversion option derivative instruments at the original note inception dates and as of March 31, 2015 using the Black-Scholes option pricing model using the share prices of the Company’s stock on the dates of valuation and using the following ranges for volatility, expected term and the risk free interest rate at each respective valuation date, no dividend has been assumed for any of the periods:

Note Inception Date

March 31, 2015

Volatility

188- 374

241

Expected Term

0.4 - 1.5 years

0.01- 1.40 years

Risk Free Interest Rate

0.12 - 2

0.14

The following reflects the initial fair value on the note inception dates and changes in fair value through March 31, 2015:

Embedded conversion option liability fair value as of December 31, 2014

2,151,502

Note inception date fair value allocated to debt discount

1,939,100

Note inception date fair value allocated to other expense

982,399

Reclassification of derivative liability to equity upon debt conversion

-752,611

Change in fair value during quarter ended March 31, 2015

-286,661

Embedded conversion option liability fair value as of March 31, 2015

4,033,729

Fair Value Measurements

We currently measure and report at fair value the liability for embedded conversion option derivatives. The fair value liabilities for price adjustable convertible debt instruments have been recorded as determined utilizing the BSM option pricing model as previously discussed. The following tables summarize our financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2015:

Balance at

Quoted

Significant

March 31,

Prices in

Other

Unobservable

2015

Active

Observable

Inputs

Markets for

Inputs

Identical

Assets

(Level 1)

(Level 2)

(Level 3)

Liabilities:

Fair value of liability for embedded conversion option derivative instruments

4,033,729

Stockholders_Deficit

Stockholders' Deficit	3 Months Ended
Stockholders' Deficit	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	5. Stockholder’s Deficit

	On August 26, 2011, the Company’s stockholders approved and adopted the PositiveID Corporation 2011 Stock Incentive Plan (the “2011 Plan”). The 2011 Plan provides for awards of incentive stock options, nonqualified stock options, restricted stock awards, performance units, performance shares, SARs and other stock-based awards to employees and consultants. Under the 2011 Plan, up to 1 million shares of common stock may be granted pursuant to awards.

	A summary of option activity under the Company’s stock incentive plans as of March 31, 2015, and changes during the three months then ended is presented below (in thousands, except per share amounts):

			Number of		Weighted
			Options		Average
					Exercise Price
					Per Share
	Outstanding at December 31, 2014			2,856	$	1.26
	Granted			1,840	$	0.01
	Exercised			—	$	—
	Forfeited			—	$	—
	Outstanding at March 31, 2015			4,696	$	0.78
	Exercisable at March 31, 2015			4,006	$	0.91

	The Black-Scholes model, which the Company uses to determine compensation expense, requires the Company to make several key judgments including:

		⋅	the value of the Company’s common stock;
		⋅	the expected life of issued stock options;
		⋅	the expected volatility of the Company’s stock price;
		⋅	the expected dividend yield to be realized over the life of the stock option; and
		⋅	the risk-free interest rate over the expected life of the stock options.

	The Company’s computation of the expected life of issued stock options was determined based on historical experience of similar awards giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations about employees’ future length of service. The interest rate was based on the U.S. Treasury yield curve in effect at the time of grant. The computation of volatility was based on the historical volatility of the Company’s common stock.

	A summary of restricted stock outstanding under the Company’s stock incentive plans as of March 31, 2015 and changes during the three months then ended is presented below (in thousands):

	Unvested at December 31, 2014			200
	Issued			—
	Vested			-100
	Forfeited			—
	Unvested at March 31, 2015			100

	Additionally, the Company has 3.2 million unvested restricted shares outstanding, not issued under stock incentive plans, which have been issued to employees, directors, and consultants. These restricted shares vest on January 1, 2016. As of March 31, 2015, 4.5 million warrants to purchase the Company’s common stock have been granted outside of the Company’s plans, which remain outstanding as of March 31, 2015. These warrants were granted at exercise prices ranging from $0.06 to $0.75 per share, are fully vested and are exercisable for a period from five to seven years.

	The Company recorded an expense related to stock options, restricted stock issued, and issuance of Series I Preferred to employees and advisors of approximately $1.0 million and $1.2 million for the three months ended March 31, 2015 and 2014, respectively.

	As of March 31, 2015 the Company had $0.3 million of unamortized compensation related to stock option and restricted share grants. This compensation will be amortized as an operating expense over the remainder of 2015, and the quarter ended March 31, 2015.

	Series I Preferred Stock

	On September 30, 2013 the Board of Directors authorized and in November 2013 the Company filed with the State of Delaware, a Certificate of Designations of Preferences, Rights and Limitations of Series I Preferred Stock (the “Certificate”). The Series I Preferred Stock ranks junior to the Company’s Series F Preferred Stock and to all liabilities of the Company and is senior to the Common Stock and any other preferred stock. The Series I Preferred Stock has a stated value per share of $1,000, a dividend rate of 6% per annum, voting rights on an as-converted basis and a conversion price equal to the closing bid price of the Company’s Common Stock on the date of issuance. The Series I Preferred Stock is required to be redeemed (at stated value, plus any accrued dividends) by the Company after three years or any time after one year, the Company may at its option, redeem the shares subject to a 10-day notice (to allow holder conversion). The Series I Preferred Stock is convertible into the Company’s Common Stock, at stated value plus accrued dividends, at the closing bid price on September 30, 2013, any time at the option of the holder and by the Company in the event that the Company’s closing stock price exceeds 400% of the conversion price for 20 consecutive trading days. The Company has classified the Series I Preferred Stock as a liability in the unaudited condensed consolidated balance sheet due to the mandatory redemption feature. The Series I Preferred Stock has voting rights equal to the number of shares of Common Stock that Series I Preferred Stock is convertible into, times twenty-five. The holders of Series I Preferred Stock will have voting control in situations requiring shareholder vote.

	On September 30, 2013, the Company issued 413 shares of Series I Preferred Stock to settle $413,000 of accrued and unpaid compensation to its Board of Directors and management, at a conversion price of $0.036, which was the closing bid price on September 30, 2013. The Series I Preferred Stock will vest on January 1, 2017, subject to acceleration in the event of conversion or redemption. The Series I Preferred may also be converted into common shares in advance of their vesting, at the option of the holder, which in turn accelerates the vesting.

	On November 5, 2013, the Company filed an Amended and Restated Certificate of Designation of Series I Preferred Stock (the “Amended Certificate of Designation”). The Amended Certificate of Designation was filed to clarify and revise the mechanics of conversion and certain conversion rights of the holders of Series I Preferred Stock. No other rights were modified or amended in the Amended Certificate of Designation. On January 8, 2015, the Company filed an amendment to the Amended Certificate of Designation to increase the authorized shares of Series I Convertible Preferred Stock from 1,000 shares to 2,500 shares. No other terms were modified or amended in the Amended Certificate of Designation.

	On December 31, 2013, the three independent directors were each granted 25 shares of Series I, as a component of their 2014 board compensation. On January 14, 2014 an additional 512 shares of Series I were issued to the Company’s CEO, President and Senior Vice President. Of these shares 381 were issued to the Company’s chief executive officer as follows: (i) 138 shares issued for 2013 incentive compensation, (ii) 143 shares were issued for his agreement to amend his employment contract and reduce his annual salary from the remainder of the term of the contract to $200,000, per annum, and (iii) 100 shares of Series I as a tax equalization payment to compensate Mr. Caragol for taxes paid on unrealized stock compensation during prior years. All Series I shares granted vest on January 1, 2017. The Series I Preferred may also be converted into common shares in advance of their vesting, at the option of the holder, which in turn accelerates vesting. As such the Company recorded an expense since vesting is at the holder’s option in the amount of $187,500, representing the fair value of the shares during the three months ended March 31, 2015.

	On January 9, 2015, shares of Series I were issued as follows: (i) 50 shares of Series I were issued to each of three independent board members as a component of their 2015 compensation (150 shares total), and (ii) 475 shares of Series I were issued to the Company’s management as a component of their 2014 incentive compensation at a conversion price of $0.027, which was the closing bid price on January 9, 2015. The Company recorded a total expense of $812,500 for the Series I shares granted which will vest on January 1, 2017. The Series I Preferred may also be converted into common shares in advance of their vesting, at the option of the holder, which in turn accelerates vesting.

Income_Taxes

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	6. Income Taxes

	The Company had an effective tax rate of nil for the three months ended March 31, 2015 and 2014. The Company incurred losses before taxes for the three months ended March 31, 2015 and 2014. However, it has not recorded a tax benefit for the resulting net operating loss carryforwards, as the Company has determined that a full valuation allowance against its net deferred tax assets was appropriate based primarily on its historical operating results.

	In July 2008, the Company completed the sale of all of the outstanding capital stock of Xmark to Stanley. In January 2010, Stanley received a notice from the Canadian Revenue Agency (“CRA”) that the CRA would be performing a review of Xmark’s Canadian tax returns for the periods 2005 through 2008. This review covers all periods that the Company owned Xmark.

	In February 2011, and as revised on November 9, 2011, Stanley received a notice from the CRA that the CRA completed its review of the Xmark returns and was questioning certain deductions attributable to allocations from related companies on the tax returns under review. In November and December 2011, the CRA and the Ministry of Revenue of the Province of Ontario issued notices of reassessment confirming the proposed adjustments. The total amount of the income tax reassessments for the 2006-2008 tax years, including both provincial and federal reassessments, plus interest, was approximately $1.4 million.

	On January 20, 2012, the Company received an indemnification claim notice from Stanley related to the matter. The Company did not agree with the position taken by the CRA, and filed a formal appeal related to the matter on March 8, 2012. In addition, on March 28, 2012, Stanley received assessments for withholding taxes on deemed dividend payments in respect of the disallowed management fee totaling approximately $0.2 million, for which we filed a formal appeal on June 7, 2012. In October 2012, the Company submitted a Competent Authority filing to the U.S. IRS seeking relief in the matter. In connection with the filing of the appeals, Stanley was required to remit an upfront payment of a portion of the tax reassessment totaling approximately $950,000. The Company has also filed a formal appeal related to the withholding tax assessments, pursuant to which Stanley was required to remit an additional upfront payment of approximately $220,000. Pursuant to a letter agreement dated March 7, 2012, the Company has agreed to repay Stanley for the upfront payments, plus interest at the rate of five percent per annum, in 24 equal monthly payments beginning on June 1, 2012. To the extent that the Company and Stanley reach a successful resolution of the matter through the appeals process, the upfront payment (or a portion thereof) will be returned to Stanley or the Company as applicable. As of March 31, 2015 the Company had made payments to Stanley of $485,777.

	On February 28, 2014 the Company received final notice from the CRA. The Company has determined that it will not further appeal the decision in the final notice. The Company and Stanley are in the process of submitting the tax forms necessary to effect the final adjustments. While the final accounting is being coordinated with CRA, the Company paid $60,000 to Stanley during the three months ended March 31, 2015. Based on management’s estimate the Company has a recorded tax contingency liability of $395,000 in the accompanying unaudited condensed consolidated financial statements as of March 31, 2015.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	7. Commitments and Contingencies

	Lease Commitments

	The Company leases certain office space under noncancelable operating leases, including the Company’s corporate offices in Delray Beach, Florida under a lease scheduled to expire in October 18, 2018 and lab and office space in Pleasanton, California under a lease which expired in April 2015 and is currently in the process of being renewed. Rent expense under operating leases totaled approximately $21,000 and $30,000 for the quarter ended March 31, 2015 and 2014, respectively.

	Other Commitments

	Pursuant to the GlucoChip Agreement (see Note 3), the Company also agreed to provide financial support to VeriTeQ, for a period of up to two years, in the form of convertible promissory notes. On October 20, 2014 and January 29, 2015, the Company funded VeriTeQ $60,000 and $40,000, respectively, and VeriTeQ issued the Company convertible promissory notes in the same amounts. The remaining support commitments for 2015 and 2016, as of March 31, 2015, are up to an additional $300,000.

	Legal Proceedings

	The Company is a party to certain legal actions, as either plaintiff or defendant, arising in the ordinary course of business, none of which is expected to have a material adverse effect on the Company’s business, financial condition or results of operations. However, litigation is inherently unpredictable, and the costs and other effects of pending or future litigation, governmental investigations, legal and administrative cases and proceedings, whether civil or criminal, settlements, judgments and investigations, claims or charges in any such matters, and developments or assertions by or against the Company relating to the Company or to the Company’s intellectual property rights and intellectual property licenses could have a material adverse effect on the Company’s business, financial condition and operating results.

Employment_Contracts_and_Stock

Employment Contracts and Stock Compensation to Related Parties	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	8. Employment Contracts and Stock Compensation to Related Parties

	On December 6, 2011, the Compensation Committee approved a First Amendment to Employment and Non-Compete Agreement (the “First Caragol Amendment”) between the Company and Mr. Caragol in connection with Mr. Caragol’s assumption of the position of Chairman of the Board of the Company effective December 6, 2011. The First Caragol Amendment amends the Employment and Non-Compete Agreement dated November 11, 2010, between the Company and Mr. Caragol and provides for, among other things, the elimination of any future guaranteed raises and bonuses, other than a 2011 bonus of $375,000 to be paid beginning January 1, 2012 in twelve (12) equal monthly payments. This bonus was not paid during 2012 and on January 8, 2013, $300,000 of such bonus was converted into 738,916 shares of our restricted common stock, which vest on January 1, 2016. The remaining $75,000 was paid through the issuance of Series I Preferred Stock (see below). The First Caragol Amendment obligates the Company to grant to Mr. Caragol an aggregate of 0.5 million shares of restricted stock over a four-year period as follows: (i) 100,000 shares upon execution of the First Caragol Amendment, which shall vest on January 1, 2014, (ii) 100,000 shares on January 1, 2012, which shall vest on January 1, 2015, (iii) 100,000 shares on January 1, 2013, which shall vest on January 1, 2015, (iv) 100,000 shares on January 1, 2014, which shall vest on January 1, 2016, and (v) 100,000 shares on January 1, 2015, which shall vest on January 1, 2016. Stock compensation expense related to the restricted share grants totaled approximately $34,000 and $34,000 for the three months ended March 31, 2015 and 2014, respectively. On January 14, 2014, Mr. Caragol’s agreement was further amended, lowering his salary to $200,000 per annum through the remaining term of the agreement in exchange for the issuance of 143 shares of Series I Preferred Stock.

	On September 28, 2012, the employment of Bryan D. Happ, our chief financial officer terminated. In connection with the termination of Happ’s Employment and Non-Compete Agreement dated September 30, 2011, we and Mr. Happ entered into a Separation Agreement and General Release, or the Separation Agreement, on September 28, 2012. Pursuant to the Separation Agreement, Mr. Happ was due to receive payments totaling $404,423, or the Compensation, consisting of past-due accrued and unpaid salary and bonus amounts plus termination compensation. Of the Compensation, $100,000 was paid with 200,000 shares of our restricted common stock (such shares not issued under a stockholder approved plan) and $304,423 was to be paid in cash. As of March 31, 2015, we have paid $184,280 of the cash balance to Mr. Happ.

Agreements_with_The_Boeing_Com

Agreements with The Boeing Company	3 Months Ended
Agreements with The Boeing Company	Mar. 31, 2015
License Agreements [Abstract]
License Agreements [Text Block]	9. Agreements with The Boeing Company

	On December 20, 2012, the Company entered into a Sole and Exclusive License Agreement (the “Boeing License Agreement”), a Teaming Agreement (“Teaming Agreement”), and a Security Agreement (“Boeing Security Agreement”) with The Boeing Company (“Boeing”).

	The Boeing License Agreement provides Boeing the exclusive license to manufacture and sell PositiveID’s M-BAND airborne bio-threat detector for the U.S. Department of Homeland Security’s BioWatch next generation opportunity, as well as other opportunities (government or commercial) that may arise in the North American market. As consideration for entering into the Boeing License Agreement, Boeing agreed to pay a license fee of $2.5 million (the “Boeing License Fee”) to the Company in three installments, which were paid in full during 2012 and 2013. The $2.5 million license fee previously received has been recorded as deferred revenue.

	At the time of entering into the Boeing Teaming and License Agreements we evaluated the Boeing license revenue recognition and concluded that all elements necessary to complete the earnings process were complete as of the date of receipt of the $2.5 million of license fees, with the exception of the completion of the terms of the Teaming Agreement, which is a delivery requirement.

	Under the Teaming Agreement, the Company retained exclusive rights to serve as the reagent and assay supplier of the M-BAND systems to Boeing. The Company also retained the rights to sell M-BAND units, reagents and assays in international markets. Upon the Teaming Agreement expiring, terminating or being replaced by a contact or subcontract, the Company expects to recognize the deferred revenue related to the Boeing License Agreement.

	Pursuant to the Boeing Security Agreement, the Company granted Boeing a security interest in all its assets, including the licensed products and intellectual property rights (as defined in Boeing License Agreement), to secure the Company’s performance under the Boeing License Agreement.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	10. Subsequent Events

	Subsequent to March 31, 2015:

		⋅	The Company has entered into additional convertible notes, pursuant to its $4 Million Convertible Debt Financing (see Note 4). The principal amount of note entered into was $500,000 (additional information disclosed in Note 4).

		⋅	Convertible notes with principal value of $261,000 have been converted into 23,893,000 shares of common stock (additional information disclosed in Note 4).

		⋅	A second note for the amount of $50,000, in conjunction with the September 22, 2014 Securities Purchase Agreement, was funded subsequent to the quarter ended March 31, 2015 (additional information disclosed in Note 4).

		⋅	1,700,000 shares of common stock with grant date value of $34,000 were issued to consultants pursuant to consulting agreements.

		⋅	The Company funded VeriTeQ $50,000 and VeriTeQ issued the Company a convertible promissory note, pursuant to the GlucoChip Agreement (additional information disclosed in Note 7), in the same amount.

		⋅	Effective April 27, 2015 the Company entered into six month consulting agreements with two service providers. On May 11, 2015 the Company issued convertible notes of $62,500, to each of the two consultants, as consideration pursuant to their consulting agreements. Each of the two notes bears interest at the rate of 8% per annum. All interest and principal must be repaid by April 27, 2017. The notes may be convertible into Common Stock, at the lower of $0.02 or a 25% discount to the price per share of the common stock at the time of conversion. The embedded conversion options in these notes will be bifurcated and presented as derivative liabilities.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
Summary of Significant Accounting Policies (Policies)	Mar. 31, 2015
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation

	The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries of which all are inactive except for MFS. All significant intercompany transactions have been eliminated in the consolidation.

Use of Estimates, Policy [Policy Text Block]	Use of Estimates

	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates during the reported periods include allowance for doubtful accounts receivable, valuation of goodwill and intangible assets, valuation of derivatives, valuation of beneficial conversion features, estimate of the contingent earn-out liability, valuation of stock-based compensation and an estimate of the deferred tax asset valuation allowance.

Goodwill and Intangible Assets, Policy [Policy Text Block]	Intangible Assets and Goodwill

	Intangible assets are carried at cost less accumulated amortization, computed using the straight-line method over the estimated useful lives. Customer contracts and relationships were previously being amortized over 3 years, patents are being amortized over 5 years, and non-compete agreements were previously being amortized over 2 years.

	The Company continually evaluates whether events or circumstances have occurred that indicate the remaining estimated useful lives of its definite-lived intangible assets may warrant revision or that the remaining balance of such assets may not be recoverable. The Company uses an estimate of the related undiscounted cash flows attributable to such asset over the remaining life of the asset in measuring whether the asset is recoverable.

	The Company records goodwill as the excess of the purchase price over the fair values assigned to the net assets acquired in business combinations. Goodwill is allocated to reporting units as of the acquisition date for the purpose of goodwill impairment testing. The Company’s reporting units are those businesses for which discrete financial information is available and upon which segment management makes operating decisions. Goodwill of a reporting unit is tested for impairment at year-end, or between testing dates if an impairment condition or event is determined to have occurred.

	In assessing potential impairment of the intangible assets recorded in connection with the MFS acquisition as of March 31, 2015, we considered the likelihood of future cash flows attributable to such assets, including but not limited to cash received from Boeing and the probability and extent of our participation in the DHS’s next generation BioWatch program and the what we believe to be a large market opportunity for our Firefly Dx product, once development is complete. Based on our analysis, we have concluded based on information currently available, that no impairment of the intangible assets exists as of March 31, 2015,.

	The Company performed an impairment test of goodwill as indicators were present as of March 31, 2015. As a result of this test, using the market capitalization method of valuation, it was determined that the goodwill balance of $510,000 as of year ended March 31, 2015, was not impaired.

Debt, Policy [Policy Text Block]	Convertible Notes With Variable Conversion Options

	The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into common shares at a fixed discount to the price of the common stock at the time of conversion. The Company measures the fair value of the notes at the time of issuance, which is the result of the share price discount at the time of conversion, and records the premium as accretion to interest expense to the date of first conversion.

	The Company accounts for debt issuance cost paid to lenders, or on behalf of lenders, in accordance with ASC 470, Debt. The costs associated with the issuance of debt are recorded as debt discount and amortized over the life of the underlying debt instrument.

Derivatives, Policy [Policy Text Block]	Accounting for Derivatives

	The Company evaluates its convertible debt, options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for. The result of this accounting treatment is that under certain circumstances the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Equity instruments that are initially classified as equity that become subject to reclassification under this accounting standard are reclassified to liability at the fair value of the instrument on the reclassification date.

Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition

	Revenue is recognized when persuasive evidence of an arrangement exists, collectability of arrangement consideration is reasonably assured, the arrangement fees are fixed or determinable and delivery of the product or service has been completed.

	If at the outset of an arrangement, the Company determines that collectability is not reasonably assured, revenue is deferred until the earlier of when collectability becomes probable or the receipt of payment. If there is uncertainty as to the customer’s acceptance of the Company’s deliverables, revenue is not recognized until the earlier of receipt of customer acceptance or expiration of the acceptance period. If at the outset of an arrangement, the Company determines that the arrangement fee is not fixed or determinable, revenue is deferred until the arrangement fee becomes estimable, assuming all other revenue recognition criteria have been met.

	To date, the Company has generated revenue from two sources: (1) professional services (consulting & advisory), and (2) technology licensing.

	Specific revenue recognition criteria for each source of revenue is as follows:

		-1	Revenues for professional services, which are of short term duration, are recognized when services are provided,

		-2	Technology license revenue is recognized upon the completion of all terms of that license. Payments received in advance of completion of the license terms are recorded as deferred revenue.

Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments and Fair Value Measurements

	The Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with ASC Topic 820, Fair Value Measurements and Disclosures (“ASC Topic 820”). For certain of our financial instruments, including cash, accounts receivable, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, also approximate fair value because current interest rates available to the Company for debt with similar terms and maturities are substantially the same.

	ASC Topic 820 provides guidance with respect to valuation techniques to be utilized in the determination of fair value of assets and liabilities. Approaches include, (i) the market approach (comparable market prices), (ii) the income approach (present value of future income or cash flow), and (iii) the cost approach (cost to replace the service capacity of an asset or replacement cost). ASC Topic 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

		Level 1:	Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

		Level 2:	Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

		Level 3:	Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

Earnings Per Share, Policy [Policy Text Block]	Loss per Common Share

	The Company presents basic income (loss) per common share and, if applicable, diluted income (loss) per share. Basic income (loss) per common share is based on the weighted average number of common shares outstanding during the year and after preferred stock dividend requirements. The calculation of diluted income (loss) per common share assumes that any dilutive convertible preferred shares outstanding at the beginning of each year or the date issued were convertible at those dates, with preferred stock dividend requirements and outstanding common shares adjusted accordingly. It also assumes that outstanding common shares were increased by shares issuable upon exercise of those stock options and warrants for which the average period market price exceeds the exercise price, less shares that could have been purchased by the Company with related proceeds. Additionally, shares issued upon conversion of convertible debt are included.

	The following potentially dilutive equity securities outstanding as of March 31, 2015 and 2014 were not included in the computation of dilutive loss per common share because the effect would have been anti-dilutive (in thousands):

			March 31,
			2015		2014
	Common shares issuable under:
	Convertible notes			245,375		12,254
	Series I Convertible preferred stock			62,064		36,460
	Series F Convertible preferred stock			—		35,887
	Stock options			4,696		2,607
	Warrants			4,490		2,629
	Unvested and restricted shares common stock			3,432		2,432
				320,057		92,269

Segment Reporting, Policy [Policy Text Block]	Segment Information

	The Company operates in a single market segment.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
Summary of Significant Accounting Policies (Tables)	Mar. 31, 2015
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following potentially dilutive equity securities outstanding as of March 31, 2015 and 2014 were not included in the computation of dilutive loss per common share because the effect would have been anti-dilutive (in thousands):

		March 31,
		2015		2014
	Common shares issuable under:
	Convertible notes		245,375		12,254
	Series I Convertible preferred stock		62,064		36,460
	Series F Convertible preferred stock		—		35,887
	Stock options		4,696		2,607
	Warrants		4,490		2,629
	Unvested and restricted shares common stock		3,432		2,432
			320,057		92,269

Equity_and_Debt_Financing_Agre1

Equity and Debt Financing Agreements (Tables)	3 Months Ended
Equity and Debt Financing Agreements (Tables)	Mar. 31, 2015
Disclosure Text Block Supplement [Abstract]
Schedule of Short-term Debt [Table Text Block]	Short-term convertible debt for the quarter ended March 31, 2015 as follows (In thousands):

		Notes			Accrued		Total
		Notes			Interest		Total

	Convertible notes with accrued interest accounted for as stock settled debt	$	379		$	34	$	413
	Conversion premiums		261			—		261
			640			34		674

	Convertible notes with embedded derivatives		3,229			137		3,366
	Derivative discounts		-2,259			—		-2,259
			970			137		1,107

	Original issue discounts and loan fee discounts		-372			—		-372
		$	1,238		$	171	$	1,409

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	The Company calculated the estimated fair values of the liabilities for embedded conversion option derivative instruments at the original note inception dates and as of March 31, 2015 using the Black-Scholes option pricing model using the share prices of the Company’s stock on the dates of valuation and using the following ranges for volatility, expected term and the risk free interest rate at each respective valuation date, no dividend has been assumed for any of the periods:

		Note Inception Date		March 31, 2015
	Volatility	188- 374	%	241	%
	Expected Term	0.4 - 1.5 years		0.01- 1.40 years
	Risk Free Interest Rate	0.12 - 2	%	0.14	%

Fair Value, Option, Quantitative Disclosures [Table Text Block]	The following reflects the initial fair value on the note inception dates and changes in fair value through March 31, 2015:

	Embedded conversion option liability fair value as of December 31, 2014	$	2,151,502

	Note inception date fair value allocated to debt discount	$	1,939,100
	Note inception date fair value allocated to other expense		982,399
	Reclassification of derivative liability to equity upon debt conversion		-752,611
	Change in fair value during quarter ended March 31, 2015		-286,661
	Embedded conversion option liability fair value as of March 31, 2015	$	4,033,729

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The following tables summarize our financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2015:

		Balance at			Quoted		Significant		Significant
		March 31,			Prices in		Other		Unobservable
		2015			Active		Observable		Inputs
					Markets for		Inputs
					Identical
					Assets
					(Level 1)		(Level 2)		(Level 3)
	Liabilities:
	Fair value of liability for embedded conversion option derivative instruments	$	4,033,729		$	-	$	-	$	4,033,729

Stockholders_Deficit_Tables

Stockholders' Deficit (Tables)	3 Months Ended
Stockholders' Deficit (Tables)	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of option activity under the Company’s stock incentive plans as of March 31, 2015, and changes during the three months then ended is presented below (in thousands, except per share amounts):

		Number of		Weighted
		Options		Average
				Exercise Price
				Per Share
	Outstanding at December 31, 2014		2,856	$	1.26
	Granted		1,840	$	0.01
	Exercised		—	$	—
	Forfeited		—	$	—
	Outstanding at March 31, 2015		4,696	$	0.78
	Exercisable at March 31, 2015		4,006	$	0.91

Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	A summary of restricted stock outstanding under the Company’s stock incentive plans as of March 31, 2015 and changes during the three months then ended is presented below (in thousands):

	Unvested at December 31, 2014		200
	Issued		—
	Vested		-100
	Forfeited		—
	Unvested at March 31, 2015		100

Organization_and_Basis_of_Pres1

Organization and Basis of Presentation (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Organization And Basis Of Presentation [Line Items]
Working Capital Deficiency	$9,100,000		$8,100,000
Retained Earnings (Accumulated Deficit), Total	-136,618,000		-132,757,000
Common Stock, Shares Authorized	1,970,000,000		1,970,000,000
Proceeds from Convertible Debt	1,600,000
Net Income (Loss) Attributable to Parent, Total	-3,861,000	-2,310,000
Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total	-1,248,000	-625,000
Common Stock [Member]
Organization And Basis Of Presentation [Line Items]
Common Stock, Shares Authorized	970,000,000
Net Income (Loss) Attributable to Parent, Total	$0
Subsequent Event [Member]
Organization And Basis Of Presentation [Line Items]
Common Stock, Shares Authorized	1,970,000,000

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	320,057	92,269
Convertible notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	245,375	12,254
Convertible Series I Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	62,064	36,460
Convertible Series F Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	35,887
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4,696	2,607
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4,490	2,629
Unvested and restricted shares common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,432	2,432

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details Textual) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Significant Accounting Policies [Line Items]
Goodwill	510	$510
Customer Contracts And Relationships [Member]
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life	3 years
Patents [Member]
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life	5 years
Non Compete Agreement [Member]
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life	2 years

AcquisitionsDispositions_Detai

Acquisitions/Dispositions (Details Textual) (USD $)	0 Months Ended	1 Months Ended		3 Months Ended	12 Months Ended	0 Months Ended
Acquisitions/Dispositions (Details Textual) (USD $)	Feb. 15, 2013	Jan. 29, 2015	Oct. 20, 2014	Mar. 31, 2015	Dec. 31, 2014	Nov. 13, 2013	Dec. 31, 2012	Dec. 31, 2011
Business Acquisition [Line Items]
Consideration For Rights And Licenses	$2,000,000
Debt Instrument, Face Amount				500,000
Number Of Strips Used Per Year	1,000
Other Commitment, Due in Next Twelve Months				300,000
Price Range 0.0025 [Member]
Business Acquisition [Line Items]
License Revenue Per Strip	0.0025
Consideration For Rights And Licenses	1,000,000
Price Range 0.005 [Member]
Business Acquisition [Line Items]
License Revenue Per Strip	0.005
Consideration For Rights And Licenses	2,000,000
Minimum [Member]
Business Acquisition [Line Items]
License Revenue Per Strip	0.0025
Class of Warrant or Right, Exercise Price of Warrants or Rights				$0.06
Maximum [Member]
Business Acquisition [Line Items]
License Revenue Per Strip	0.005
Class of Warrant or Right, Exercise Price of Warrants or Rights				$0.75
Note II [Member]
Business Acquisition [Line Items]
Debt Instrument, Interest Rate During Period		10.00%	10.00%
VeriTeQ warrant [Member]
Business Acquisition [Line Items]
Trading Securities, Realized Gain				95,000
Proceeds from Warrant Exercises				781,376	820,010
VeriTeQ [Member]
Business Acquisition [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						300,000
Class of Warrant or Right, Exercise Price of Warrants or Rights						$2.84
Debt Instrument, Face Amount							222,115	222,115
Proceeds from Warrant Exercises						852,000
Notes Receivable, Related Parties, Current				322,115	282,115
VeriTeQ [Member] \| Note I [Member]
Business Acquisition [Line Items]
Debt Instrument Unamortized Discount Percentage				40.00%
VeriTeQ [Member] \| Note II [Member]
Business Acquisition [Line Items]
Debt Instrument, Face Amount		40,000	60,000
Debt Instrument, Term			2 years
Debt Instrument, Description			The continuing financial support is not required to be more frequent than every 100 days and may not be in excess of $50,000 in any individual note.

Equity_and_Debt_Financing_Agre2

Equity and Debt Financing Agreements (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Convertible Notes With Accrued Interest Accounted For As Stock Settled Debt [Member]
Short-term Debt [Line Items]
Notes Payable	$379
Debt Instrument, Increase, Accrued Interest	34
Short-term Debt, Maximum Amount Outstanding During Period	413
Conversion premiums [Member]
Short-term Debt [Line Items]
Notes Payable	261
Debt Instrument, Increase, Accrued Interest	0
Short-term Debt, Maximum Amount Outstanding During Period	261
Convertible Notes With Accrued Interest Accounted For As Stock Settled Debt Net [Member]
Short-term Debt [Line Items]
Notes Payable	640
Debt Instrument, Increase, Accrued Interest	34
Short-term Debt, Maximum Amount Outstanding During Period	674
Convertible Notes With Embedded Derivatives [Member]
Short-term Debt [Line Items]
Notes Payable	3,229
Debt Instrument, Increase, Accrued Interest	137
Short-term Debt, Maximum Amount Outstanding During Period	3,366
Derivative Discounts [Member]
Short-term Debt [Line Items]
Notes Payable	-2,259
Debt Instrument, Increase, Accrued Interest	0
Short-term Debt, Maximum Amount Outstanding During Period	-2,259
Convertible Notes With Embedded Derivatives Net [Member]
Short-term Debt [Line Items]
Notes Payable	970
Debt Instrument, Increase, Accrued Interest	137
Short-term Debt, Maximum Amount Outstanding During Period	1,107
OID And Loan Fees Discount [Member]
Short-term Debt [Line Items]
Notes Payable	-372
Debt Instrument, Increase, Accrued Interest	0
Short-term Debt, Maximum Amount Outstanding During Period	-372
Convertible Notes Payable [Member]
Short-term Debt [Line Items]
Notes Payable	1,238
Debt Instrument, Increase, Accrued Interest	171
Short-term Debt, Maximum Amount Outstanding During Period	$1,409

Equity_and_Debt_Financing_Agre3

Equity and Debt Financing Agreements (Details 1)	3 Months Ended
Equity and Debt Financing Agreements (Details 1)	Mar. 31, 2015
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Volatility	241.00%
Risk Free Interest Rate	0.14%
Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected Term	1 year 4 months 24 days
Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected Term	4 days
Note Inception Date [Member] \| Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Volatility	374.00%
Expected Term	1 year 6 months
Risk Free Interest Rate	2.00%
Note Inception Date [Member] \| Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Volatility	188.00%
Expected Term	4 months 24 days
Risk Free Interest Rate	0.12%

Equity_and_Debt_Financing_Agre4

Equity and Debt Financing Agreements (Details 2) (USD $)	3 Months Ended
Equity and Debt Financing Agreements (Details 2) (USD $)	Mar. 31, 2015
Fair Value, Option, Quantitative Disclosures [Line Items]
Embedded conversion option liability fair value as of December 31, 2014	$2,151,502
Note inception date fair value allocated to debt discount	1,939,100
Note inception date fair value allocated to other expense	982,399
Reclassification of derivative liability to equity upon debt conversion	-752,611
Change in fair value during quarter ended March 31, 2015	-286,661
Embedded conversion option liability fair value as of March 31, 2015	$4,033,729

Equity_and_Debt_Financing_Agre5

Equity and Debt Financing Agreements (Details 3) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Defined Benefit Plan Disclosure [Line Items]
Fair value of liability for embedded conversion option derivative instruments	$4,033,729	$2,151,502
Fair Value, Measurements, Recurring [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of liability for embedded conversion option derivative instruments	4,033,729
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of liability for embedded conversion option derivative instruments	0
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of liability for embedded conversion option derivative instruments	0
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of liability for embedded conversion option derivative instruments	$4,033,729

Equity_and_Debt_Financing_Agre6

Equity and Debt Financing Agreements (Details Textual) (USD $)	0 Months Ended	3 Months Ended		0 Months Ended	12 Months Ended	0 Months Ended	1 Months Ended	0 Months Ended		1 Months Ended	0 Months Ended	1 Months Ended		0 Months Ended	1 Months Ended		0 Months Ended		1 Months Ended			12 Months Ended	0 Months Ended	1 Months Ended
	Mar. 13, 2014	Mar. 31, 2015	Mar. 31, 2014	Sep. 07, 2012	Dec. 31, 2012	5-May-14	Jun. 18, 2014	Jul. 03, 2014	Jul. 07, 2014	Aug. 21, 2014	Jul. 09, 2014	Jul. 17, 2014	Aug. 19, 2014	Sep. 04, 2014	Sep. 22, 2014	Apr. 24, 2015	Oct. 06, 2014	Oct. 08, 2014	Oct. 27, 2014	Nov. 25, 2014	Dec. 24, 2014	Dec. 31, 2014	Mar. 10, 2015	Sep. 24, 2014	Mar. 31, 2015	Apr. 06, 2015	Jul. 09, 2012	Jan. 08, 2015
Equity And Debt Financing Agreements [Line Items]
Proceeds from Convertible Debt		$1,600,000
Convertible Debt		4,000,000																							4,000,000	88,319
Debt Instrument, Face Amount		500,000																							500,000
Derivative Liability		3,610,885																							3,610,885
Convertible Debt Discount			1,857,600
Amortization, Total			27,000
Percentage Of Lowest Closing Price In 20 Trading Days	40.00%
Convertible Notes Payable [Member]
Equity And Debt Financing Agreements [Line Items]
Debt Instrument, Face Amount																							24,772
H K Note [Member]
Equity And Debt Financing Agreements [Line Items]
Repayments of Notes Payable		340,556
Gross Proceeds Threshold From An Acquisition Or Disposition Of Assets																											750,000
Gross Proceeds Threshold From Completion Of Any Financing																											1,500,000
Gross Proceeds Threshold From Receipt Of Any Revenues																											750,000
Gross Proceeds Threshold From Any One Financing Or Licensing Arrangement																											3,000,000
Secured Debt		508,594																							508,594		849,510
Caragol Note [Member]
Equity And Debt Financing Agreements [Line Items]
Debt Instrument, Interest Rate, Stated Percentage				5.00%
Repayments of Notes Payable					100,000
Secured Debt		91,572		200,000																					91,572
Financing Threshold Amount Triggering Accelerated Repayment Of Related Party Debt				1,500,000
Proceeds from Related Party Debt				200,000
Convertible Note Financing On March 13, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities	16,386,485
Proceeds from Convertible Debt	65,750					65,750
Debt Instrument, Face Amount	75,000
Debt Instrument, Maturity Date	4-Mar-15
Amortization of Debt Discount (Premium)		100,000				50,000
Percentage Of Lowest Closing Price In 20 Trading Days	40.00%
Proceeds From Convertible Debt Gross	75,000					75,000
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate	8.00%
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	75,000
Debt Instrument, Unamortized Premium																						50,000
Convertible Note Financing On March 13, 2014 [Member] \| Convertible Notes Payable [Member]
Equity And Debt Financing Agreements [Line Items]
Proceeds From Convertible Debt Gross		75,000
Convertible Note Financing On June 18 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Debt Instrument, Convertible, Conversion Price							$0.08
Debt Instrument, Face Amount							165,000
Debt Discount As Percentage							10.00%
Interest Charge As Percentage							10.00%
Percentage Of Lowest Closing Price In 20 Trading Days							40.00%
Convertible Note Financing On July 3, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities		8,248,677
Debt Instrument, Convertible, Conversion Price								$0.06
Proceeds from Convertible Debt								100,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								1,000,000
Debt Instrument, Face Amount								115,000
Derivative Liability								59,623
Debt Instrument, Maturity Date								3-Jul-15
Amortization of Debt Discount (Premium)		58,571
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate								8.00%
Percentage Of Lowest Closing Price In 15 Trading Days								40.00%
Share Price								$0.08
Warrants Not Settleable in Cash, Fair Value Disclosure		41,429																							41,429
Additional Convertible Note Financing On March 13, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities	9,482,870
Convertible Note Financing On July 7, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Proceeds from Convertible Debt									50,000
Convertible Debt		56,182																							56,182
Debt Instrument, Face Amount									53,000
Debt Instrument, Maturity Date									25-Mar-15
Common Stock Discount Percentage									39.00%
Amortization of Debt Discount (Premium)									33,885
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate									8.00%
Convertible Note Financing On July 9, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Stock Issued During Period, Value, New Issues											49,444
Proceeds from Convertible Debt										180,000	180,000
Convertible Debt		279,705									222,222														279,705
Debt Instrument, Face Amount										110,000	110,000
Derivative Liability		204,079								289,701	289,701														204,079
Common Stock Discount Percentage											37.50%
Amortization of Debt Discount (Premium)		186,656								271,666	271,666
Debt Discount As Percentage										10.00%	10.00%
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate										10.00%	10.00%
Percentage Of Lowest Closing Price In 15 Trading Days										40.00%	40.00%
Debt Instrument, Unamortized Premium										146,666	146,666
Convertible Note Financing On July 17, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Debt Instrument, Unamortized Discount		100,000																							100,000
Debt Instrument, Convertible, Conversion Price												$0.06
Proceeds from Convertible Debt												100,000
Convertible Debt																												120,750
Debt Instrument, Face Amount												115,000
Derivative Liability												124,666
Debt Instrument, Convertible, Remaining Discount Amortization Period												10 years
Debt Instrument, Maturity Date												17-Jul-16
Debt Discount As Percentage												10.00%
Percentage Of Lowest Closing Price In 20 Trading Days												40.00%
Convertible Note Financing On August 19, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Debt Instrument, Unamortized Discount		54,500																							54,500
Debt Instrument, Convertible, Conversion Price													$0.06
Proceeds from Convertible Debt													54,500
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		5,000,000																							5,000,000
Debt Instrument, Face Amount													66,000
Derivative Liability													71,548
Debt Instrument, Maturity Date													15-Aug-15
Debt Discount As Percentage													10.00%
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate													8.00%
Percentage Of Lowest Closing Price In 15 Trading Days													60.00%
Convertible Note Financing On September 4, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities		9,195,341
Debt Instrument, Interest Rate, Stated Percentage														10.00%
Debt Instrument, Convertible, Conversion Price														$0.04
Proceeds from Convertible Debt														100,000
Debt Instrument, Face Amount														110,000
Derivative Liability														119,246
Amortization of Debt Discount (Premium)		100,000												10,000
Percentage Of Lowest Closing Price In 25 Trading Days														60.00%
Convertible Note Financing On September 22, 2014 One [Member]
Equity And Debt Financing Agreements [Line Items]
Proceeds from Convertible Debt															50,000
Convertible Debt		47,124																							47,124
Debt Instrument, Face Amount															54,750
Debt Instrument, Maturity Date															19-Jun-15
Common Stock Discount Percentage															40.00%
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate															8.00%
Debt Instrument, Unamortized Premium															36,500
Convertible Note Financing On September 22, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Proceeds from Convertible Debt															45,000
Convertible Debt		5,199																							5,199
Debt Instrument, Face Amount															100,000
Common Stock Discount Percentage															40.00%
Amortization of Debt Discount (Premium)															33,333
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate															8.00%
Convertible Note Financing On September 22, 2014 [Member] \| Subsequent Event [Member]
Equity And Debt Financing Agreements [Line Items]
Proceeds from Convertible Debt																45,000
Debt Instrument, Unamortized Premium																33,333
Convertible Note Financing On October 6, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Proceeds from Convertible Debt																	50,000
Convertible Debt		73,641																							73,641
Debt Instrument, Face Amount																	53,000
Debt Instrument, Maturity Date																	1-Jun-15
Common Stock Discount Percentage																	39.00%
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate																	8.00%
Debt Instrument, Unamortized Premium																	33,885
Convertible Note Financing On October 8, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities		7,590,186
Proceeds from Convertible Debt																		85,500
Convertible Debt		104,086																							104,086
Debt Instrument, Face Amount																		100,000
Convertible Debt Discount																		7,500
Debt Instrument, Maturity Date																		30-Mar-15
Legal Fees																		7,000
Common Stock Discount Percentage																		40.00%
Amortization of Debt Discount (Premium)																		66,667
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate																		10.00%
Convertible Note Financing On October 27, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Proceeds from Convertible Debt																			33,250
Convertible Debt		38,216																							38,216
Debt Instrument, Face Amount																			36,750
Debt Instrument, Maturity Date																			21-Oct-15
Percentage Of Lowest Closing Price In 20 Trading Days																			40.00%
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate																			8.00%
Debt Instrument, Unamortized Premium		24,500																							24,500
Debt Instrument, Repurchase Amount		52,892																							52,892
Convertible Note Financing On October 27, 2014 Two [Member]
Equity And Debt Financing Agreements [Line Items]
Proceeds from Convertible Debt																			150,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																			1,000,000
Convertible Debt																			167,422
Debt Instrument, Face Amount																			161,000
Convertible Debt Discount																			11,000
Debt Instrument, Maturity Date																			27-Oct-15
Common Stock Discount Percentage																			40.00%
Amortization of Debt Discount (Premium)		52,215																	107,333
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate																			8.00%
Share Price																			$0.08
Warrants Not Settleable in Cash, Fair Value Disclosure		33,404																							33,404
Convertible Note Financing On October 27, 2014 Two [Member] \| Subsequent Event [Member]
Equity And Debt Financing Agreements [Line Items]
Convertible Debt																										166,681
Convertible Note Financing On November 25, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Proceeds from Convertible Debt																				3,840,000
Debt Instrument, Face Amount																				4,000,000
Amortization, Total		276,357
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate																				12.00%
Debt Instrument, Periodic Payment																				500,000
Reimbursement Expenses For Purchaser																				25,000
Reimbursement Expenses For Purchasers Counsel																				25,000
Percentage Of Conversion Price Of Note Into Common Stock On Closing Price																				95.00%
Percentage Of Conversion Price Of Note Into Common Stock																				62.50%
Percentage Of Premium On Convertible Note																				120.00%
Original Issue Discount Rate																				4.00%
Debt Instrument, Convertible, Terms of Conversion Feature																				In the event that there is an Event of Default or certain conditions are not met, the conversion price will be adjusted to equal to 55% of the lowest VWAP during the thirty (30) Trading Days immediately prior to the applicable Conversion Date.
Ironridge and Dominion Capital LLC Financing [Member]
Equity And Debt Financing Agreements [Line Items]
Stock Issued During Period, Shares, Other		30,354,196
Convertible Debt		4,000,000																			158,400				4,000,000
Derivative Liability		165,622																			571,387				165,622
Debt Instrument, Maturity Date																					31-May-15
Amortization of Debt Discount (Premium)		491,407																			522,061
Debt, Current		164,649																			434,592				164,649
Convertible Note Financing On March 31, 2015 [Member]
Equity And Debt Financing Agreements [Line Items]
Debt Instrument, Convertible, Conversion Price		$106,000																							$106,000
Proceeds from Convertible Debt		2,244,600																				500,000
Convertible Debt		2,716,460																							2,716,460
Derivative Liability		3,474,979																							3,474,979
Convertible Debt Discount		387,000																							387,000
Original Issue Discount Rate		4.00%
Monthly Funding Amount		500,000																							500,000
Convertible Note Financing On March 31, 2015 [Member] \| Additional [Member]
Equity And Debt Financing Agreements [Line Items]
Proceeds from Convertible Debt		150,000
Convertible Note Financing On March 10, 2015 [Member]
Equity And Debt Financing Agreements [Line Items]
Debt Instrument, Convertible, Conversion Price																							$0.02
Proceeds from Convertible Debt																							56,778
Convertible Debt		82,381																							82,381
Debt Instrument, Face Amount																							24,722
Derivative Liability		92,333																					96,915		92,333
Common Stock Discount Percentage																							37.50%
Amortization of Debt Discount (Premium)		24,670																					81,500
Convertible Note Financing On September 24, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities		4,955,411
Proceeds from Convertible Debt																								67,750
Debt Instrument, Face Amount																								75,000
Amortization of Debt Discount (Premium)		50,000
Percentage Of Lowest Closing Price In 20 Trading Days																								40.00%
First Tranche [Member] \| Convertible Note Financing On June 18 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities		3,750,000
Debt Instrument, Unamortized Discount							50,000
Proceeds from Convertible Debt							50,000
Convertible Debt		51,051																							51,051
Debt Instrument, Face Amount							55,000
Derivative Liability		5,712					59,623																		5,712
Stock Issued During Period, Value, Conversion of Convertible Securities		8,545
Debt Instrument, Maturity Date							17-Jun-16
Amortization of Debt Discount (Premium)		56,394
Second Tranche [Member] \| Convertible Note Financing On June 18 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Proceeds from Convertible Debt							50,000
Convertible Debt		58,195																							58,195
Debt Instrument, Face Amount							55,000
Derivative Liability		42,026					59,623																		42,026
Debt Instrument, Maturity Date							19-Sep-15
Amortization of Debt Discount (Premium)		25,048					50,000
First Note [Member] \| Convertible Note Financing On September 22, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities		361,073
Debt Instrument, Face Amount															50,000
Second Note [Member] \| Convertible Note Financing On September 22, 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Debt Instrument, Face Amount															50,000
Third Tranche [Member] \| Convertible Note Financing On June 18 2014 [Member]
Equity And Debt Financing Agreements [Line Items]
Proceeds from Convertible Debt							50,000
Convertible Debt		56,492																							56,492
Debt Instrument, Face Amount							55,000
Derivative Liability		48,978					62,858																		48,978
Debt Instrument, Maturity Date							22-Dec-15
Amortization of Debt Discount (Premium)		28,193					50,000
First Five Tranches [Member]
Equity And Debt Financing Agreements [Line Items]
Proceeds from Convertible Debt		299,400
First Five Tranches [Member] \| Convertible Note Financing On March 31, 2015 [Member]
Equity And Debt Financing Agreements [Line Items]
Proceeds from Convertible Debt																									2,150,000
Convertible Note Financings [Member] \| Ironridge and Dominion Capital LLC Financing [Member]
Equity And Debt Financing Agreements [Line Items]
Convertible Debt																					$4

Stockholders_Deficit_Details

Stockholders' Deficit (Details) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding - Number Of Options	2,856
Granted - Number Of Options	1,840
Exercised - Number Of Options	0
Forfeited - Number Of Options	0
Outstanding - Number Of Options	4,696
Exercisable - Number Of Options	4,006
Outstanding - Weighted Average Exercise Price	$1.26
Granted - Weighted Average Exercise Price	$0.01
Exercised - Weighted Average Exercise Price	$0
Forfeited - Weighted Average Exercise Price	$0
Outstanding - Weighted Average Exercise Price	$0.78
Exercisable - Weighted Average Exercise Price	$0.91

Stockholders_Deficit_Details_1

Stockholders' Deficit (Details 1)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested at beginning of year	200
Issued	0
Vested	-100
Forfeited	0
Unvested at end of year	100

Stockholders_Deficit_Details_T

Stockholders' Deficit (Details Textual) (USD $)	0 Months Ended	1 Months Ended	3 Months Ended		12 Months Ended		0 Months Ended
Stockholders' Deficit (Details Textual) (USD $)	Jan. 09, 2015	Sep. 30, 2013	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Jan. 12, 2015	Jan. 08, 2015	Nov. 05, 2013	Aug. 26, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Total			$985,000	$1,158,000
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number One			3,200,000
Stock Issued During Period, Shares, Share-based Compensation, Gross	150
Percentage Of Closing Stock Price Exceeds Of Conversion Price		400.00%
Series I Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred Stock, Par or Stated Value Per Share		1,000
Preferred Stock, Dividend Rate, Percentage		6.00%
Stock Issued During Period, Shares, Issued for Services		413
Conversion Of Stock Conversion Price	0.027
Preferred Stock, Shares Authorized		0.036
Series I Preferred Stock [Member] \| Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Issued for Services					512
Series I Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	812,500
Preferred Stock, Shares Authorized								2,500	1,000
Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Date						1-Jan-17
Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Officers Compensation					200,000
Chief Executive Officer [Member] \| Series I Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Issued for Services					100
Stock Issued During Period, Shares, New Issues						381
Board Of Directors And Management [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred Compensation Liability, Current, Total		413,000
Director [Member] \| Series I Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Issued for Services					25
Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, New Issues			1,700,000
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights			$0.06
Minimum [Member] \| Chief Executive Officer [Member] \| Series I Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Issued for Services					138
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			7 years
Class of Warrant or Right, Exercise Price of Warrants or Rights			$0.75
Maximum [Member] \| Chief Executive Officer [Member] \| Series I Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Issued for Services					143
Stock Incentive Plan 2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total										1,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			4,500,000
Stock Options and Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation, Total			1,000,000	1,200,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total			300,000
Board Compensation 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value			$187,500
Incentive Compensation 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross	50
Incentive Compensation 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross							475

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	1 Months Ended
Income Taxes (Details Textual) (USD $)	Oct. 31, 2012	Mar. 31, 2015	Mar. 28, 2012	Mar. 07, 2012	Dec. 31, 2011
Operating Loss Carryforwards [Line Items]
Income Tax Examination, Penalties and Interest Accrued, Total			$200,000
Number Of Equal Monthly Payments				24
Outstanding Amount		485,777
Loss Contingency Accrual		395,000
Tax Reassessment [Member]
Operating Loss Carryforwards [Line Items]
Income Tax Examination, Penalties and Interest Expense, Total	950,000
Withholding Tax Assessments [Member]
Operating Loss Carryforwards [Line Items]
Income Tax Examination, Penalties and Interest Expense, Total	220,000
Subsequent Event [Member] \| Minimum [Member]
Operating Loss Carryforwards [Line Items]
Income Tax Examination, Penalties and Interest Accrued, Total		60,000
Xmark Corporation [Member]
Operating Loss Carryforwards [Line Items]
Income Tax Examination, Penalties and Interest Accrued, Total					$1,400,000

Commitments_and_Contingencies_

Commitments and Contingencies (Details Textual) (USD $)	3 Months Ended
Commitments and Contingencies (Details Textual) (USD $)	Mar. 31, 2015	Mar. 31, 2014	Jan. 29, 2015	Oct. 20, 2014
Operating Leases, Rent Expense	$21,000	$30,000
Commitments Amount Funded			40,000	60,000
Other Commitment, Due in Next Twelve Months	$300,000
Lease Expiration Date	18-Oct-18
Lease Expiration Period	Apr-15

Employment_Contracts_and_Stock1

Employment Contracts and Stock Compensation to Related Parties (Details Textual) (USD $)	0 Months Ended	3 Months Ended		12 Months Ended	1 Months Ended
	Jan. 08, 2013	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Sep. 28, 2012	Dec. 31, 2011
Stock Issued During Period, Shares, Restricted Stock Award, Gross
Stock Compensation To Related Party		$34,000	$34,000
Stock Issued During Period, Shares, Restricted Stock Award, Gross	738,916
Officer Compensation Payment Description		On January 14, 2014, Mr. Caragols agreement was further amended, lowering his salary to $200,000 per annum through the remaining term of the agreement in exchange for the issuance of 143 shares of Series I Preferred Stock.
Chief Executive Officer [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross
Officers Compensation				200,000
Board of Directors Chairman [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross
Accrued Bonuses, Current						375,000
Bonus Amount Converted For Restricted Stock Shares	300,000
Board of Directors Chairman [Member] \| Restricted Stock [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross
Bonus Amount Converted For Restricted Stock Shares	500,000
Board of Directors Chairman [Member] \| Series I Preferred Stock [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross
Accrued Bonuses, Current	75,000
Board of Directors Chairman [Member] \| January 1 2014 [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross
Stock Issued During Period, Shares, Restricted Stock Award, Gross		100,000
Board of Directors Chairman [Member] \| January 1 2015 [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross
Stock Issued During Period, Shares, Restricted Stock Award, Gross		100,000
Board of Directors Chairman [Member] \| January 1 2015 One [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross
Stock Issued During Period, Shares, Restricted Stock Award, Gross		100,000
Board of Directors Chairman [Member] \| January 1 2016 One [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross
Stock Issued During Period, Shares, Restricted Stock Award, Gross		100,000
Board of Directors Chairman [Member] \| January 1 2016 Two [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross
Stock Issued During Period, Shares, Restricted Stock Award, Gross		100,000
Chief Financial Officer [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross
Accrued Compensation Expenses					404,423
Officers Compensation		184,280			100,000
Stock Compensation To Related Party Paid In Cash					$304,423
Chief Financial Officer [Member] \| Restricted Stock [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross
Stock Issued During Period, Shares, Restricted Stock Award, Gross					200,000

Agreements_with_The_Boeing_Com1

Agreements with The Boeing Company (Details Textual) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2015
License Agreements [Line Items]
Licenses Revenue	$2.50	$2.50
Number Of License Payment Installments			3
Deferred Revenue			$2.50

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (USD $)	3 Months Ended		0 Months Ended
Subsequent Events (Details Textual) (USD $)	Mar. 31, 2015	Mar. 31, 2014	11-May-15	Apr. 06, 2015	Dec. 31, 2012	Dec. 31, 2011	Mar. 10, 2015
Subsequent Event [Line Items]
Debt Instrument, Face Amount	$500,000
Convertible Debt	4,000,000			88,319
Debt Conversion, Converted Instrument, Amount	907,000	95,000
Debt Conversion, Converted Instrument, Shares Issued	23,893,000
Common Stock, Conversion Basis	The notes may be convertible into Common Stock, at the lower of $0.02 or a 25% discountto the price per share of the common stock at the time of conversion.The embedded conversion options in these notes will be bifurcated and presented as derivative liabilities.
Consultants [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues	1,700,000
Stock Issued During Period, Value, New Issues	34,000
VeriTeQ [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount					222,115	222,115
Payments to Fund Long-term Loans to Related Parties	50,000
September 22, 2014 Securities Purchase Agreement [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount	50,000
Convertible Notes Payable [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount							24,772
Debt Conversion, Converted Instrument, Amount	261,000
Subsequent Event [Member] \| Service Provider Two [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount			$62,500
Debt Instrument, Interest Rate During Period			8.00%
Debt Instrument, Maturity Date			27-Apr-17